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 Activator Protein-1(AP-1) family plays a central role in the transcriptional 
regulation of many genes that are associated with cell proliferation, migration, metastasis, 
and survival. Transforming growth factor beta (TGF-β) is a multifunctional regulatory 
cytokine that regulates many aspects of cellular function, including cellular proliferation, 
migration, and survival. This study investigated the role of FOS proteins in TGF-β 
signaling in prostate cancer cell proliferation, migration, and invasion. DU145 and PC3 
prostate cancer cells were exposed to TGF-β1 at varying time and dosage, RT-PCR, 
western blot and immunofluorescence analyses were used to determine TGF-β1 effect on 
FOS mRNA and protein expression levels as well as FosB subcellular localization. 
Transient silencing of FOS protein was used to determine their role in cell proliferation, 
migration and invasion. Our data showed that FOS mRNA and proteins were 
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differentially expressed in human prostate epithelial (RWPE-1) and prostate cancer cell 
lines (LNCaP, DU145, and PC3). TGF-β1 induced the expression of FosB at both the 
mRNA and protein levels in DU145 and PC3 cells, whereas cFos and Fra1 were 
unaffected and Fra2 protein expression increased in PC3 cell only. Immunofluorescence 
analysis showed an increase in the accumulation of FosB protein in the nucleus of PC3 
cells after treatment with exogenous TGF-β1. Selective knockdown of endogenous FosB 
by specific siRNA did not have any effect on cell proliferation in PC3 and DU145 cells. 
However, basal and TGF-β1-and EGF- induced cell migration was significantly reduced 
in DU145 and PC3 cells lacking endogenous FosB. TGF-β1- and EGF-induced cell 
invasion were also significantly decreased after FosB knockdown in PC3 cells. Transient 
silencing of Fra2 resulted in decrease in cell proliferation in PC3 cells whereas transient 
silencing of cFos resulted in an increase in cell number in PC3 cells. And lastly, TGF-β1 
reduced FosB: cJun dimerization; cJun knockdown increased cell migration in PC3 cells 
and its overexpression decreased cell migration in DU145 cells. Our data suggest that 
FosB is required for migration and invasion in prostate cancer cells. We also conclude 
that TGF-β1 effect on prostate cancer cell migration and invasion may be mediated 
through the induction of FosB 
 
 
ACTIVATOR PROTEIN-1 IN TRANSFORMING GROWTH FACTOR-BETA 









SUBMITTED TO THE FACULTY OF CLARK ATLANTA UNIVERSITY 
IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR 




CACHÉTNE SAMOIS X. BARRETT 
 
































I would like to express my special appreciation to my dissertation advisor, Dr. 
Shafiq A. Khan, for encouraging my research and for allowing me to grow as a research 
scientist. I would also like to thank my Dissertation Advisory Committee for serving as 
my committee members and for their brilliant comments and suggestions. They are: Drs. 
Jaideep Chaudhary, Valerie Odero-Marah, Xiu-Ren Bu, and Adegboyega Oyelere. I 
would like to thank current and former members of Dr. Khan’s lab: Cecille Ana Millena, 
Dr. Silvia Caggia, Dr. Bethtrice Elliott, Clement J. Bolton II, Mawiyah Kimbrough-
Allah, and Smrruthi Venugopal. My sincerest gratitude goes to my aunt and uncle, Alma 
and Del Forbes; and my friends, Trishanna Harris, MarTia Adams, Jacole Todd, and 
Nikita King. I would like to especially thank my mother, Jacinth Barrett; my sisters, 
Marsha Minott, Tamequa Minott, and Tahjétne Clark; my brother, Jomo Minott; my 
nieces and nephews; and my Elizabeth Baptist Church Family. Words cannot express 
how grateful I am for all of the sacrifices made on my behalf. Their constant prayers for 
me sustained me thus far and inspired me to strive towards my goal. Finally, I would like 
to express my heartfelt appreciation to my beloved Heavenly Father, whose guidance, 
provision, and protection brought me here. Thanks be to God. This study was supported 




TABLE OF CONTENTS 
ACKNOWLEDGEMENTS………………………………………………………………iii 
LIST OF FIGURES……………………………………………………………………...vii 
LIST OF ABBREVIATIONS ………………………………….………………………ix 
 
CHAPTER  
I. INTRODUCTION ............................................................................................ 1 
Background and Significance ........................................................................... 1 
Rationale ......................................................................................................... 13 
Research Question .......................................................................................... 14 
Hypothesis/Specific Aims ............................................................................... 15 
II. LITERATURE REVIEW ............................................................................... 21 
Prostate and Prostate Cancer ........................................................................... 21 
Transforming Growth Factor-Beta ................................................................. 27 
Transforming Growth Factor-Beta in Prostate Development and Function ... 31 
Activator Protein-1.......................................................................................... 35 
Activator Protein-1 in Cancers and Prostate Cancer …………………..…….41 
Activator Protein-1 in TGF-β Signaling ……………..…………………...…42 
AP-1 Proteins in TGF-β Signaling and Prostate Cancer………….…….……43 
III. MATERIALS AND METHODS .................................................................... 44 
Chemicals and Reagents ................................................................................. 44 
Human Prostate Cancer Cell Lines ................................................................. 44 





RNA Isolation, cDNA Synthesis, and RT-PCR.............................................. 45 
Western Blot Analyses ……………………………………………………....46 
Immunoflurescence of FosB ………………………………………………...47 
Transfections ……………………………………………………………...…48 
Cell Proliferation Assays …………………………………………………....50 
Cell Migration Assays ……………………………………………………….51 
Cell Invasion Assays ………………………………………………………...51 
Co-immunoprecipitation …………………………………………………….52 
Statistical Analyses ………………………………………………………….53 
IV. RESULTS ....................................................................................................... 54 
Expression of FOS Family Members in Prostate Cancer Cells  ..................... 54 
TGF-β Effects on FOS protein Expression and Nuclear Accumulation ......... 56 
FosB Knockdown on TGF-β1 mediated cell prolifaretion, migration ............ 58 
And Invasion 
FOS Family Members Role in Prostate Cancer Cell Growth ……………….61 
and Poliferation 
TGF-β1 Effect on AP-1 dimerization ……………………………………….65 






A. Table 1……………………………………………………………………….76 
 
vi  





 LIST OF FIGURES 
Figure                                                                                                                              
 1.  TGF-β role in cancer ................................................................................................ .3 
  2.  Schematic of TGF-β signaling  ................................................................................ 5 
  3.  Prostate anatomy and prostate cancer risk factors ................................................. .21 
  4.  Leading sites of new cancer cases and deaths-2016 estimates ............................... 23 
      5.  Stages of prostate cancer  ....................................................................................... 25 
  6.  Transformed metastatic prostate cells  ................................................................... 26 
      7.  Schematic representation of TGF-β-receptors  ...................................................... 29 
      8.  TGF-β1 in prostate cancer progression ................................................................. .33 
   9.  Schematic diagram showing JUN and FOS molecular structure  ......................... 38 
 10.  FOS family basal expression  ................................................................................ 55 
 11. TGF-β1 on FOS Family mRNA and protein expression  ....................................... 57 
     12.  The effect of FosB knockdown on TGF-β1-induced prostate cancer cell                        
           Proliferation ........................................................................................................... 59 
13.  The effect of FosB knockdown on TGF-β1-induced prostate cancer cell  
Migration............................................................................................................... 60 
 14.  Effects of FosB knockdown on prostate cancer cell invasion  .............................. 61 
     15.  The effect of cFos and Fra1 knockdown on prostate cancer cell number  ........... 63 
     16.  Effects of Fra2 knockdown on prostate cancer cell proliferation  ........................ 64
  
viii  
    17.  FOS family knock down on prostate cancer cell morphology  .............................. 65 
    18.  The effect of TGF-β1 on FosB: cJun dimerization ................................................ 66 
    19.   The effect of cJun knockdown on prostate cancer cell migration  ....................... 67 




LIST OF ABBREVIATIONS 
AKT               Protein Kinase B 
AMH               Anti-Müllerian Hormone 
ANOVA  Analysis of Variance 
AP-1              Activator Protein 1 
ATF               Activating Transcription Factor 
bp               base pair 
BMPs              Bone Morphogenetic Proteins 
BSA              Bovine Serum Albumin 
bZIP               Basic Leucine Zipper Domain 
CDC42  Cell Division Control Protein 42 
cDNA               Complementary Deoxyribonucleic Acid 
CSCs               Cancer Stem Cells 
DAPI               4’-6-Diamidino-2-phenylindole 
DBD               DNA Binding Domain 
DNA               Deoxyribonucleic Acid 
dNTP               Dinucleotide Triphosphate 
ECL               Enhanced Chemiluminescence 
EGF               Epidermal Growth Factor 
ERK1/2  Extra-cellular Signal Regulated Kinases 




Fra1               Fos-Like Antigen 1 
Fra2               Fos-Like Antigen 2 
FOS              Finkel-Biskis-Jinkins murine osteogenic sarcoma virus 
GDF               Growth and Differentiation Factor 
GTPase  Guanosine Triphosphate Hydrolytic Enzymes 
HIPK2              Homeodomain Interacting Protein Kinase 2 
IE               Immediate Early 
IgG-HRP Immunoglobulin Horseradish Peroxidase 
JNK              JUN N-Terminal Kinases 
KSFM              Keratinocyte Serum Free Medium 
LAP              Latency-associated Peptide 
LZD              Leucine Zipper Domain 
MAPK              Mitogen-activated Protein Kinases 
MEM              Minimum Essential Medium 
MIS              Müllerian Inhibiting Substance 
MMP1              Matrix Metalloproteinase 
mRNA              Messenger Ribonucleic Acid 
MTS              3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) -2-(4-
sulfophenyl)- 
                          2H-tetrazolium inner salts 
MTT              3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
mTOR              Mechanistic Target of Rapamycin 
NCBI              National Center for Bioinformatics 




NIH              National Institutions of Health 
NLM              National Library of Medicine 
PAI1               Plasminogen Activator Inhibitor 1 
PBS               Phosphate Buffered Saline 
PCa                Prostate Cancer 
PCR               Polymerase Chain Reaction 
PI3K               Phosphoinositide-3-Kinases 
PSA               Prostate Specific Antigen 
PTEN               Phosphatase and Tensin Homolog 
PVDF               Polyvinylidene Difluoride 
RAC1               Ras-Related C3 Botulinum Substrate 1 
RT               Reverse Transcriptase 
Rh               recombinant human 
Rho               Rhodopsin 
RNA               Ribonucleic Acid 
RPMI               Roswell Park Memorial Institute 
SARA               Smad Anchor for Receptor Activation 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
Smad              Mothers against Decapentaplegic 
SOX4              SRY-Related HMG-Box 4 
TAD              Transactivation Domain 
TβRI              Transforming Growth Factor-β Type I Receptor 




TGF-β              Transforming Growth Factor-β 
TPA              12-O-Tetradecanoyl-phorbol-13-acetate 
TRE              TPA-Response Element 







Background and Significance 
Cancer is a key health issue across the world, causing substantial patient 
morbidity and mortality.1 Prostate cancer (PCa.) is the most common malignant disease in 
males and the second leading cause of cancer related deaths in men in developed 
countries.2-3 Prostate cancer accounts for 28% of cancer diagnoses and 10% of cancer 
deaths in men.3 Patients with localized prostate cancer have a relatively long-term 
survival due to great advances in surgical resection and adjuvant therapy.4 However, 
patients with advanced, especially metastatic bone disease are often associated with a 
poor prognosis.4 Studies have shown that around 30% of these patients will develop 
distant metastases within five years of diagnosis, even after radical surgery.4 Bone 
metastases occur in more than 80% of cases of advanced-stage prostate cancer, which 
confers a high level of morbidity, with a five-year survival rate of 25% and a median 
survival of approximately 40 months.4 Patient prognosis is tightly linked with metastatic 
dissemination of the disease to distant sites, with metastatic diseases accounting for a vast 
percentage of cancer patient mortality.1 A critical barrier for the successful prevention 




eradication of metastatic and therapy-resistant disease.5 While advances in this area have 
been made, the process of cancer metastasis and the factors governing cancer spread and 
establishment at secondary locations are still poorly understood.6   
With rare exceptions, the natural history of all types of tumors is known to 
progress from localized indolent stages to aggressive metastatic stages.7-9 Recent 
advancements in biomarker research have made significant progresses to help prediction 
of cancer progression and disease outcome.9-12 However, the molecular mechanisms 
behind tumor progression remain elusive. Transforming growth factor beta (TGF-β) is 
known to inhibit cell cycle in benign cells but promote progression and metastasis in 
cancer cells (Figure 1),9, 13-14 a phenomenon known as TGF-β paradox.9, 15 Although there 
are numerous articles with different approaches tackling this topic, to date, a logical 






Figure 1: The Role of TGF-β in Cancer; In normal and premalignant cells, TGFβ 
enforces homeostasis and suppresses tumor progression directly through cell-autonomous 
tumor-suppressive effects (cytostasis, differentiation, apoptosis) or indirectly through 
effects on the stroma (suppression of inflammation and stroma-derived mitogens). 
However, when cancer cells lose TGFβ tumor-suppressive responses, they can use TGFβ 
to their advantage to initiate immune evasion, growth factor production, differentiation 
into an invasive phenotype, and metastatic dissemination or to establish and expand 
metastatic colonies. 
 
The TGF-β superfamily comprises TGF-β1–3, bone morphogenetic proteins 
(BMPs), growth and differentiation factors (GDFs), Nodal, activins/inhibins, Müllerian 
inhibiting substance (MIS)/anti-Müllerian hormone (AMH), and Lefty. These ligands 




original identification.18-21 As it becomes clear that most ligands play multiple functions 
depending on cell type, developmental stage, or tissue conditions, they are now classified 
by sequence similarity and the downstream pathway they activate.22 Each family member 
has an overall basic structure, in which inactive forms are produced with an N-terminal 
secretion peptide and a large pro-peptide domain known as latency-associated peptide 
(LAP). Cleavage of the pro-peptide domain by pro-protein convertases releases a mature 
domain at the C-terminus, which eventually dimerizes.23 The pro-peptide domain has 
major regulatory roles. It influences protein stability and functions as chaperone during 
secretion, also mediating diffusion through interactions with the extracellular matrix and 
inhibiting the active peptide form even after cleavage.24-26 Secreted cytokines of the TGF-
β family are found in all multicellular organisms and implicated in regulating 
fundamental cell behaviors such as proliferation, differentiation, migration and survival.23 
Virtually, all types of cells produce and are sensitive to TGF-β superfamily members.27 
TGF-β is a pleiotropic factor with several different roles in health and disease.28-29 As 
stated earlier, in cancer, TGF-β plays a paradoxical role, it represses epithelial tumor 
development in the early steps of tumorigenesis, while in advanced stages it can stimulate 
tumor progression.29-31 In epithelial cells, TGF-β has anti-proliferative and apoptotic roles 
which enable it to reverse local mitogenic stimulation in the pre-tumoral stage in the 
epithelium.29 During the advance of tumorigenesis, carcinoma cells acquire resistance to 
the proliferative inhibition and apoptosis induced by TGF-β. Several mechanisms have 
been described to explain the changes in the response of tumor cells to TGF-β1, including 




Mammals express three genetically distinct isoforms of TGF-𝛽 (TGF-𝛽1, TGF-
β2, and TGF-β3) with high homology. The TGF-β1, β2, and β3 genes are located on 
chromosomes 19q13, 1q41, and 14q24, respectively.28-29 TGF-𝛽 initiates signaling by 
binding to cell-surface serine/threonine kinase receptors types I and II (TβRI and TβRII, 
respectively), which form a heteromeric complex in the presence of the dimerized ligand 
(Figure 2).  
 
Figure 2. Schematic Diagram of TGF-β Signaling from Cell Membrane to the Nucleus 
The arrows indicate signal flow and are color coded: orange for ligand and receptor 
activation, gray for Smad and receptor inactivation, green for Smad activation and 
formation of a transcriptional complex, and blue for Smad nucleocytoplasmic shuttling. 
Phosphate groups and ubiquitin are represented by green and red circles, respectively. 
 
Binding of TGF-𝛽 to TβRII leads to the phosphorylation of TβRI, thus activating its 
kinase domain.29, 32 When the receptor complex is activated, it phosphorylates and 




Smad2/3 releases them from the inner surface, where they are specifically retained by 
Smad anchor for receptor activation (SARA). Further on, Smad2/3 forms a heterotrimeric 
complex with the common Smad4, which is then translocated into the nucleus where, in 
collaboration with other transcription factors, it binds and regulates promoters of different 
target genes.28-29, 33 In addition to Smad signaling, TGF-𝛽1 may activate other intracellular 
signaling pathways, called non-Smad pathways, such as mitogen-activated protein 
kinases (MAPK): ERK1,2, JNK and p38; PI3K (phosphoinositide 3-kinase)/AKT1/2 and 
mTOR, known as cell survival mediators; NF-𝜅B (nuclear factor 𝜅B), Cyclooxygenase-2, 
and prostaglandins; and the small GTPase proteins Ras, Rho family (Rho, Rac1 and 
Cdc42), among others.29, 34-35 
  TGF-β overproduction is a universal event in cancer cells and is a poor 
prognostic marker.29, 36-40 The mechanism, through which TGF-β regulates its own 
production, is different between benign and cancer cells. Under the normal physiological 
conditions, the level of TGF-β is tightly regulated within the microenvironment through a 
negative feedback loop to maintain a relatively constant level of TGF-β. Too little or too 
much TGF-β will have an unfavorable consequence.29, 41-43 However, this principle does 
not apply to cancer. Cancer cells, especially the advanced cases, are capable of evading 
the immune surveillance program due to the well-known phenomenon of auto-induction 
of TGF-β by cancer cells,29 resulting in an elevated TGF-β in the microenvironment 
through a positive feedback loop.29, 44 As a result, there is an accumulation of TGF-β in the 
microenvironment, which further promotes tumor progression.29, 36, 39, 45 According to the 




carcinoma initiation, progression and metastasis through a broad and complex spectrum 
of interdependent interactions.30 The knowledge about the mechanisms involved in TGF-
β signal transduction has allowed a better understanding of the disease pathogenicity as 
well as the identification of several molecular targets with great potential in therapeutic 
interventions.28  
It is also becoming apparent that TGF-β signaling intersects with several 
transcription factors and regulators, such as GL1, SOX4, Tieg3/Klf11, Id, and AP-1 
proteins.46-50 Many studies have implicated Activator Protein-1 (AP-1) proteins in TGF-β 
signaling.50-52 Numerous studies have characterized the differential expression of specific 
genes in response to TGF-β, revealing a common link in the ability of TGF-β to regulate 
many of these genes through the functions of the AP-1 family of transcription factors.53 
The ability of TGF-β to induce the expression of several genes, including PAI-1, 
clusterin, monocyte chemoattractant protein-1 (JEyMCP-1), type I collagen, and TGF-β1 
itself depends on specific AP-1 DNA-binding sites in the promoter regions of these 
genes.53-58 Furthermore, TGF-β-mediated transcriptional activation of several of these 
genes requires AP-1 proteins.53-54, 56-58 Intriguingly, the expression of many AP-1 proteins 
themselves is induced as an early response to TGF-β in a cell type-specific manner.53, 59-60 
It has been demonstrated that this induced expression of particular AP-1 family members 
is involved in TGF-β-mediated regulation of subsequent target genes.53, 58 In addition, 
genetic studies of TGF-β signaling in Drosophila melanogaster reveal a direct overlap 
between AP-1 and TGF-β signaling and suggest an evolutionarily conserved convergence 




signaling and AP-1 proteins in the TGF-β-regulated expression of various genes. The 
molecular mechanisms responsible for the TGF-β-mediated transcriptional activation of 
these genes are just beginning to be elucidated.53 
The AP-1 family consists of dimeric protein complexes composed of different Jun 
proteins (c-Jun, JunB, and JunD) and four FOS proteins (c-Fos, FosB, Fra1, and Fra2). 
These proteins form Jun-Jun homodimers and Jun-Fos heterodimers and bind to the 12-
O-tetradecanoylphorbol-13-acetate response element, TGACTCA palindromic sequence, 
in the promoters of target genes.50, 62-63 AP-1 proteins have been shown to be involved in 
cell proliferation, inflammation, differentiation, apoptosis, wound healing, and 
carcinogenesis.50, 64-65 The transcription factor AP-1 converts extracellular signals into 
changes in the expression of specific target genes which harbor AP-1-binding site(s) in 
their promoter and enhancer regions. AP-1 proteins are certainly important participants 
and possibly determinant factors in the diverse mechanisms that contribute to the 
development of human cancers, although casual proof for these functions is yet to be 
established. The fact that AP-1 is positioned as a signal responsive transcription factor 
complex at the end of a large number of signaling cascades, makes it very likely that AP-
1 components could provide the missing link between growth factor signaling and the 
cell cycle machinery.  
c-Fos and c-Jun have been extensively characterized and studied following their 
identification as the original components of AP-l.66 Accordingly, a number of researchers 
assume that what 'has been mostly worked for Jun' (and Fos) 'serves as a useful paradigm 




of induction, modes of regulation and transactivation properties of each of these genes, 
this view can only hold true to a point.66 Ultimately, each FOS and JUN gene member 
should be investigated individually to gain a better understanding of the overall function 
of AP-1.66 Previous studies in our laboratory have elucidated the roles of JUN proteins in 
prostate cancer cell proliferation giving rise to this research project’s focus on 
understanding the individual roles of FOS family members in prostate cancer cell 
development and progression. 
AP1 mediation of cellular response to growth factors is suggested by the 
observation that deregulated expression of certain members of the Fos and Jun families 
results in the neoplastic transformation of susceptible cells.68  Studies revealed that AP-1 
DNA binding activity is not a single transcription factor but a dimer.69 Different AP-1 
subunits display functional diversity in a cell-type specific manner 70 and different subsets 
of AP-1 proteins have differing dimerization requirements.71 cJun, for example, can 
homo- and heterodimerize while cFos can only form heterodimers. These AP-1 dimers 
regulate a wide variety of cellular processes including the immune response, cell 
proliferation, apoptosis, and tumorigenesis.63, 71 Different dimer compositions showed 
promoter-specific differences in activating transcription of reporter genes.71-73 The role of 
AP-1 proteins has been widely studied; however, discerning the distinct roles of 
individual dimer compositions remains challenging.71 This project arose from studies 
indicating that JunD plays an essential role in the proliferation of prostate cancer 
epithelial cancer cells.50 It has also been suggested by several studies that expression of 




patients.50, 74-75 Most of these studies have, however, focused on the expression and/or 
function of activated AP-1 complex containing c-Jun and c-Fos.50, 76 Consequently, the 
specific functions of individual AP-1 family members and various homo- and 
heterodimers in the regulation of specific cellular processes remain largely unknown.50 
Studies also showed that Jun-Fos dimers that have similar DNA binding specificities can 
differ in transcriptional activity due to non-conserved domains located outside the bZIP 
region that can be regulated by phosphorylation. It is therefore plausible that AP-1 dimers 
of different composition execute specific cellular programs.73 With this in mind it is our 
desire to decipher the individual roles of the FOS family members in prostate cancer cell 
proliferation, migration and invasion and in the process determine which FOS family 
member could be the partner for JunD and is essential for prostate cancer cell 
proliferation. 
cFos has been found to induce differentiation of certain cell types,66, 77 and to also 
transform cells following its overexpression and removal of part of its 3' untranslated 
region.66, 78 cFos may repress its own transcriptional activation and the activation of other 
genes such as Egr-l,66, 79 in addition to trans-activating the expression of genes like 
collagenase and Fra-1.66, 80-81 In oral cancer it has been observed that cFos/JunD 
heterodimer together showed higher transcriptional activity than JunD/JunD 
homodimers.73, 82 Therefore, it was speculated that JunD/JunD homodimer formation 
might prevent the precancerous cells entering into cancerous condition, but as soon as 
participation of cFos member takes place in AP-1 complex formation, the precancerous 




significantly correlate with high MMP9 expression and both proteins are weakly 
associated with a positive nodal status in breast cancer patients.83-85 cFos expression also 
correlated with cyclin E which is another indicator of unfavorable outcome in breast 
cancer patients.85-86 In transient transfection experiments, cFos overexpression led to a 
weak (1.65–1.81-fold) stimulation of migration and invasion through matrigel 
membranes in MCF7 cells, whereas in MDA-MB231 cells, the invasive potential was 
non-significantly enhanced independent of cell migration.85 These data point to a 
stimulating effect of cFos on cell invasion and are in accordance with its oncogenic 
function observed in various cell systems.85, 87 
FosB expression is statistically associated with a well-differentiated, estrogen- 
and progesterone- receptor positive phenotype of breast cancer samples, FosB expression 
was associated with higher levels of the cell-cycle inhibitor Rb and low expression of the 
proliferation marker Ki67.85-86 FosB expression was statistically associated with the 
collagenase MMP1, which also correlates with a positive estrogen receptor status, and 
surprisingly, with a nodal-negative tumor type.85 In invasion assays with breast cancer 
cell lines, FosB had no significant influence on invasion of MDA-MB231 cells, whereas 
in MCF7 cells, the number of invasive cells was significantly increased after transient 
transfection with FosB expression vectors.85 Yet, the stimulating effect was even stronger 
in control inserts without matrigel membrane indicating that in MCF7 cells, FosB 
stimulates cell migration through the pores of the insert bottom, whereas the relative 
number of invasive cells is not increased.85 These data suggest that in mammary 




mice lacking FosB develop normally but display a profound nurturing defect whereas, 
overexpression of ΔFosB (an alternative spliced form of FosB which lacks transactivation 
activity but binds JUN proteins and DNA with similar efficiency as FosB) interferes with 
normal cell differentiation.88 
Like other AP-1 subunits, Fra1 has been recently linked to multiple cancers, 
including breast, bladder, colon and esophagus cancers and head and neck squamous cell 
carcinoma.70 Fra1 is highly expressed in many epithelial cancers including squamous cell 
carcinoma of the skin (cSCC) and head and neck squamous cell carcinoma (HNSCC). 
However, the functional importance and the mechanisms mediating Fra1 function in 
these cancers are not fully understood.70 While c-Jun was required for the expression of 
the G1/S phase cell cycle promoter CDK4, Fra1 was essential for AKT activation and 
AKT-dependent expression of CyclinB1, a molecule required for G2-M progression.70 
Exogenous expression of a constitutively active form of AKT rescued cancer cell growth 
defect caused by Fra1-loss.70 Additionally, Fra1 knockdown markedly slowed cell 
adhesion and migration, and conversely expression of an active Fra1 mutant (Fra1DD) 
expedited these processes in a JNK/c-Jun-dependent manner.70 Fra1 only weakly 
transforms rat embryo fibroblasts and causes no overt morphological transformation of 
rat embryo fibroblasts.66, 81 The weak transforming potential of Fra-1 is due to a lack of a 
C-terminal transactivation domain,66 and so Fra-1 tends to repress the expression of IE 
genes,66, 79 particularly in combination with JunB and c-Jun.66, 89 However, when 
complexed with JunD, Fra-1 may stimulate AP-l-dependent transcription.66, 89 Fra-1 




in more differentiated breast cancer cell lines (MCF7, T47D).85 In clinical tumor tissues, 
only very low Fra-1 protein levels were found by Western blot analysis.85 Prior study on 
mammary carcinomas, showed Fra-1 expression was significantly associated with a 
poorly differentiated, estrogen-receptor negative phenotype and strong Ki67 and Cyclin E 
expression.85-86 
Invasion assays showed a significant increase of the invasive potential after 
forced Fra-2 overexpression in MDA-MB231, but not MCF7 cells. In clinical tumor 
tissue, total Fra-2 expression was significantly associated with high Cyclin D1 and Cyclin 
E expression.85-86 Fra-2 protein levels and expression of the more slowly migrating, 
phosphorylated Fra-2 bands correlated with high expression of MMP9, PAI-1 (both 
indicators of unfavorable outcome) and the PAI-1/uPA and PAI-1/tPA complexes.85 In 
addition, those same studies showed a significantly higher frequency of recurrence in 
patients with high levels of the phosphorylated Fra-2.85 
Rationale 
Prostate cancer (PCa) is the most diagnosed cancer and the second leading cause 
of cancer death among men in the United States.90-91 TGF-β was originally described as 
being one of the most potent polypeptide growth inhibitors isolated from natural 
sources.92 TGF-β is a secreted cytokine that acts as a major anti-proliferative factor in the 
initial stages of prostate cancer, whereas in the advanced stages of prostate cancer, it 
acquires pro-oncogenic and pro-metastatic properties.50, 93-95Deregulation of TGF-β 
expression or signaling has been implicated in the pathogenesis of a variety of diseases, 




development, TGF-β is actively secreted by tumor cells and does not merely act as a 
bystander but rather contributes to the cell growth, invasion, and metastasis and decreases 
host-tumor immune response.96-97 Activator protein-1 (AP-1) was one of the first 
transcription factors to be identified, but its physiological functions are still being 
unraveled. AP-1 activity is induced by a plethora of physiological stimuli and 
environmental insults98 such as growth factors, cytokines, tumor-promoters and UV-
irradiation.99 In turn, AP-1 regulates a wide range of cellular processes, including cell 
proliferation, death, survival and differentiation.98 Although AP-1 proteins share a high 
level of sequence and function homology, they exhibit distinct expression patterns and 
differ in their transcriptional and biological activities.100   
Research Question 
Previous studies have shown different effects of TGF-β1 on proliferation of 
different prostate cancer cell lines; TGF-β inhibits proliferation of DU145 cells but has 
no effect on proliferation of PC3 cells in the presence of functional TGF-β receptors and 
Smad signaling,101-104 indicating differences in signaling mechanisms in two cell lines 
downstream of receptor-dependent Smad activation that are responsible for differential 
effects of TGF-β on cell proliferation.50 Other intracellular proteins influence TGF-β 
effects,50, 105-107 and studies have shown that TGF-β signaling interacts with several 
transcription factors including AP-1. In prostate cancer, expression of AP-1 proteins has 
been associated with disease recurrence and more aggressive clinical outcome.50, 108-109 
Previous studies have shown that without JunD prostate cancer cells do not proliferate, 




proliferation in prostate cancer cells; considering the fact that AP-1 proteins must 
function as dimers, neither JunB or cJun knockdown affected prostate cancer cell 
proliferation, and that JUN proteins are able to both homo and heterodimerize, the 
question becomes: which AP-1 protein could potentially be a partner for JunD and is 
required for prostate cancer cell proliferation to occur? In an attempt to answer this 
question there are some other primary queries that must be answered. Therefore, this 
project is designed to determine: 1) Are FOS family proteins expressed in prostate cancer 
cell lines and is their expression being regulated by TGF-β? 2) Does the presence of 
TGF-β influence FOS protein subcellular localization and dimerization? 3) Are FOS 
proteins involved in TGF-β effects on prostate cancer cell proliferation, migration, and 
invasion? 
Hypothesis 
With these questions in mind we hypothesize that JunD is essential for prostate 
cancer cell proliferation; therefore, without JunD, prostate cancer tumors would not 
develop. In addition, JunD does not work alone; it requires another AP-1 partner such as 
a member of JUN or FOS family to exert its effects on cancer cell proliferation and tumor 
development. JUN and FOS proteins share extensive homology within the leucine zipper 
and basic domains. However, despite their homology, these proteins display different 
transcriptional activity. Therefore, we also hypothesize that the FOS proteins contribute 
distinct functions towards the activity of the AP-1 heterodimers and that TGF-β1 could 
induce the expression of FOS proteins and these proteins could play an important role in 




Specific Aims  
 In an attempt to test the above hypotheses and answer the research questions 
discussed above, the following aims have been addressed:  
Specific Aim 1: To determine the basal expression of FOS family members (FosB, cFos, 
Fra1, and Fra2) mRNA and protein in normal prostate epithelial cells and prostate cancer 
cells, and determine if their expression is regulated by TGF-β1. 
Rationale: The transcription factor AP-1 is activated in response to an incredible array 
of stimuli, including mitogenic growth factors, inflammatory cytokines, growth factors of 
the TGF-β family, UV and ionizing irradiation, cellular stress, antigen binding, and 
neoplastic transformation.110 The AP-1 transcription factor consists of a large set of dimer 
combinations formed between the Jun, Fos and ATF families of proteins.111-113 AP-1 
activity converts extracellular signals into changes in gene expression patterns through 
the binding of AP-1 dimers to specific target sequences located within the promoters and 
enhancers of target genes. These targets include genes important for regulating many 
biological processes including proliferation, differentiation, apoptosis and 
transformation.110, 112, 114-115 AP-1 activity functions in a hierarchy: dimerization of AP-1 
proteins is required for DNA binding that in turn leads to transcriptional activity.112 TGF-
β acts as a tumor suppressor in early stages of the tumor development, and then switches 
to a tumor promoter in later stages of tumor development52, 62-63 through undefined 
mechanisms. Many TGF-β1 regulated genes have AP-1 binding sites53-58 and AP-1 
themselves are being regulated by TGF-β1.53, 59-60 Previous studies in our lab showed that 




mRNA level but exhibited differences in the levels of JUN proteins in various cell lines, 
indicating differential regulation of proteins in different cell lines.50 These results also 
showed that TGF-β induces a reduction in JunD protein levels in DU145 cells but not in 
PC3 cells. Because JunD is required for cell proliferation, these results suggest that 
reduction of JunD levels in DU145 cells in response to TGF-β may lead to reduction in 
cell proliferation in these cells.50 On the other hand, the lack of TGF-β effects on PC3 cell 
proliferation may be due to their resistance to TGF-β-induced reduction of JunD levels.50  
Previous studies have revealed the response of JUN proteins to TGF-β1 stimulation and 
even demonstrated that JunD is essential for TGF-β1-induced effects on prostate cancer 
cell proliferation; however, it is still unclear whether FOS proteins are influenced by 
TGF-β1 and could be essential for TGF-β effects on prostate cancer cell growth and 
progression. 
Experimental Design: The steady state expression of FOS mRNA and protein was 
determined using prostate and prostate cancer epithelial cells seeded in 10 cm dishes and 
allowed to grow for 48 hours; at which point the cells will be lysed and both RNA and 
protein will be extracted and analyzed for FOS mRNA and protein expression using 
reverse transcription polymer chain reaction (RT-PCR) and Western Blot respectively. 
Next, DU145 and PC3 prostate cancer cells lines will be seeded to 80% confluency in 6-
welled plates and treated with 5ng/ml of exogenous TGF-β1 at varying time points (0-8 
hours) as well as varying concentrations of TGF-β1 (0-10ng/ml) for four hours. The cells 




Blot analyses. This should reveal the effects of TGF-β1 on FOS mRNA and protein 
expression. 
Specific Aim 2: To determine the effects of FOS family members in TGF-β regulated cell 
proliferation, migration and invasion of prostate cancer cells.  
Rationale: AP-1 subunits bind to a common DNA site, the AP-1-binding site. As the 
complexity of our knowledge of AP-1 factors has increased, our understanding of their 
physiological function has decreased.114 This trend, however, is beginning to be reversed 
due to the recent studies of gene-knockout mice and cell lines deficient in specific AP-1 
components.114 Such studies suggest that different AP-1 factors may regulate different 
target genes and thus execute distinct biological functions.114 Also, the involvement of AP-
1 factors in functions such as cell proliferation and survival has been made somewhat 
clearer as a result of such studies.114 In addition, there has been considerable progress in 
understanding some of the mechanisms and signaling pathways involved in the 
regulation of AP-1 activity.114 AP-1 activity is regulated in a given cell by a broad range 
of physiological and pathological stimuli, including cytokines, growth factors, stress 
signals and infections, as well as oncogenic stimuli.62 Regulation of net AP-1 activity can 
be achieved through changes in transcription of genes encoding AP-1 subunits, control of 
the stability of their mRNAs, posttranslational processing and turnover of pre-existing or 
newly synthesized AP-1 subunits, and specific interactions between AP-1 proteins and 
other transcription factors and cofactors.62 Previous studies in our lab using transfection 
of DU145 and PC3 prostate cancer cells with  JunD siRNA caused a significant 




inhibition, p < 0.05) cells. On the other hand, knockdown of either c-Jun or JunB had no 
significant effect on cell proliferation in both cell lines. These results suggested that JunD 
is required for proliferation of both DU145 and PC3 cells.50 However, the specific roles 
of individual AP-1 family members in the development and progression of prostate 
cancer are still largely unknown. 
Experimental Design: DU145 and PC3 cells lines will be seeded in 6-welled plates and 
grown to 80 % confluency; the cells will be transiently transfected to knockdown the FOS 
proteins using siRNA specific for FosB, cFos, Fra1 and Fra2. The transfected cells will 
be used to perform proliferation, migration and invasion assays (MTT, transwell inserts 
and matrigel, respectively). 
Specific Aim 3: To identify which AP-1 protein(s) dimerizes with JunD and is/are 
essential for regulating cell proliferation in prostate cancer cells. 
Rationale: Recent studies using cells and mice deficient in individual AP-1 proteins have 
begun to shed light on their physiological functions in the control of cell proliferation, 
neoplastic transformation and apoptosis.115 The main characteristic of the AP-1 
complexes in the cell is their heterogeneity in dimer composition.113 This heterogeneity is 
caused by the fact that multiple AP-1 sub-units can be expressed at the same time, 
including c-Jun, JunB, JunD, c-Fos, FosB, Fra1, Fra2, ATF2, ATFa and ATF3.113 The 
actual activities of JUN: FOS depend on the cell type, its differentiation state and the 
type of stimuli it has received.113 Earlier studies have shown that dimerization is a 
requirement for activation of AP-1 proteins and that AP-1 proteins form multiple homo- 




genes involved in specific biological responses. However, the specific roles of individual 
AP-1 family members in the development and progression of prostate cancer are still 
largely unknown. Few reports have shown the effects, if any, of TGF-β on AP-1 in 
prostate cancer.116-118  
Experimental Design: DU145 and PC3 cells lines will be seeded in 6-welled plates and 
grown to 80 % confluency; the cells will be transiently transfected to knockdown the FOS 
proteins using siRNA specific for FosB, cFos, Fra1 and Fra2. The transfected cells will 







Prostate and Prostate Cancer  
 The prostate, an androgen-regulated exocrine gland, is an integral part of the male 
reproductive system (Figure 3A) which has an essential function in sperm survival and 
motility.119 It is located immediately below the bladder and just in front of the bowel. Its 
main function is to produce fluid which protects and enriches sperm. In younger men, the 






Figure 3: The Prostate A) Anatomy of the human prostate, B) Normal prostate compared 
to an enlarged prostate, C) Factors that promote prostate health, D) Factors that enhance 
prostate cancer risks 
 
It is doughnut shaped as it surrounds the beginning of the urethra (the tube that conveys 
urine from the bladder to the penis). The nerves that control erections surround the 
prostate.91 Prostate cancer is usually one of the slower growing cancers. In the past, it was 
most frequently encountered in men over 70, and many of those men died of other causes 
before their prostate cancer could kill them.120 This led to the old saying “most men die 
with, not of, prostate cancer.” However, that is certainly not true today. Three 
developments have changed things considerably: 1) Men are living longer, giving the 
cancer more time to spread beyond the prostate, with potentially fatal consequences. 2) 
More men in their early sixties, fifties and even forties are being diagnosed with prostate 
cancer.120 Earlier onset combined with the greater male life expectancy means those 
cancers have more time to spread and become life-threatening unless diagnosed and 
treated. 3) Prostate cancer in younger men often tends to be more aggressive and hence 
more life-threatening within a shorter time. Those diagnosed at a young age have a higher 
cause-specific mortality than men diagnosed at an older age, except those over age 80 
years.120 Early-onset prostate cancer has a strong genetic component, which indicates that 
young men with prostate cancer could benefit from evaluation of genetic risk.120 
Furthermore, although the majority of men with early-onset prostate cancer are diagnosed 
with low-risk disease, the extended life expectancy of these patients exposes them to 
long-term effects of treatment-related morbidities and to long-term risk of disease 
progression leading to death from prostate cancer.120
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Prostate cancer is the most diagnosed and the second leading cause of cancer 
deaths among American men (Figure 4).  
 
According to American Cancer Society, 180,896 men will be diagnosed and 26,120 men 
will die of prostate cancer in US in 2016. Cancer statistics for 2016 indicates that apart 
from skin cancer prostate cancer is the most frequently diagnosed cancer in men. For 
reasons that remain unclear, the risk of prostate cancer is 70% higher in blacks than in 
non-Hispanic whites. With an estimated 26,120 deaths in 2016, prostate cancer is the 
second-leading cause of cancer death in men. Prostate cancer death rates have been 
decreasing since the early 1990s in men of all races/ethnicities, although they remain 
more than twice as high in blacks as in any other group. Overall, prostate cancer death 
rates decreased by 3.5% per year from 2003 to 2012 (American Cancer Society. Cancer 
Facts & Figures 2016. Atlanta: American Cancer Society; 2016). These declines are due 
to improvements in early detection and treatment. Early prostate cancer usually has no 
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symptoms. With more advanced disease, men may experience weak or interrupted urine 
flow; difficulty starting or stopping the urine flow; the need to urinate frequently, 
especially at night; blood in the urine; or pain or burning with urination. Advanced 
prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, 
ribs, or other areas. There are currently no practices that will guarantee prevention of 
prostate cancer; however, there are habits and life style practices that are encouraged as 
ways to reduce a man’s risk of acquiring the disease (Figure 3C). As well as some 
practices that could potentially increase a man’s risks of getting the disease (Figure 3D). 
Early stage prostate cancer (Figure 5) which is localized in the prostate gland is 
treatable by surgery and radiation therapy and the prognosis in these patients is very 
good.121 Many of these treatments provide men with very little benefit in terms of life 
expectancy, but subject them to considerable harm. For instance, one in two is impotent, 
one in ten needs to wear pads because of urine leakage and one in ten has back passage 
problems. Currently, treating prostate cancer depends on: the stage of the cancer, the 
Gleason score, the level of prostate specific antigen (PSA) in the blood stream, the man’s 
age and general health, and the side effects of the treatments. According to the Prostate 
Cancer Foundation, treatments may include: image guided radiotherapy and intensity 
modulated radiotherapy, active surveillance, surgery, external beam radiotherapy, 
brachytherapy, hormone therapy, and high intensity focused ultrasound. Most of these 
treatments are specific for the localized cancer; once the cancer has escaped from the 





Figure 5:  Stage I, Earliest stage, where the cancer is so small that it cannot be felt on 
rectal examination, but is discovered in a prostate biopsy or in prostate tissue that has 
been surgically removed to ‘unblock’ the flow of urine (as in a transurethral resection of 
the prostate – TURP). Stage II, The tumor can now be felt on rectal examination, but is 
still confined to the prostate gland and has not spread. Stage III, The tumor has spread 
outside the gland and may have invaded the seminal vesicles. Stage IV, The tumor has 
spread to involve surrounding tissues such as the rectum, bladder or muscles of the pelvis 
and lymph nodes. 
 
Prostate cancers in later stages of disease metastasize (Figure 6) to other tissues 
and bone and pose a significant problem for treatment.121 Prostate cancer cells eventually 
break out of the prostate and invade distant parts of the body, particularly the bones and 
lymph nodes, producing secondary tumors, a process known as metastasis. Once the 
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cancer escapes from the prostate, treatment is possible, but “cure” as we know it becomes 
impossible. Death from prostate cancer results when cancer cells become metastatic after 
invading the lymph nodes and blood vessels and migrate to bone.122-123 
 
Figure 6: Transformed metastatic prostate cells escape from the prostate into blood 
vessels to eventually invade distant organs. 
 
The most frequent sites of metastasis are lymph nodes and bone; 90% of patients who die 
of prostate cancer harbor bone metastases.124-125 Current treatments for metastatic disease 
are hormonal therapy and chemotherapy. Hormonal therapies are based on inhibition of 
biosynthesis and/or action of androgens.126-127 However, the cancer cells develop resistance 
to these treatments resulting in development of castration resistant or hormone refractory 
prostate cancers. There is no effective therapy for these cancers which are responsible for 
mortality in majority of patients. 
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Metastasis is the cause of most prostate cancer deaths,128 approximately 80% of 
metastatic prostate cancers exhibit some degree of bone metastasis.129 The most typical 
locations of the metastases are pelvic lymphatic glands, bones and lungs, and very rarely 
it metastasizes into a testis.130 Bubendorf et al., in the series of 1589 patients with the 
prostate carcinoma, showed that 35% of the patients had hematogenous metastases, 
mostly in bones (90%), the lungs (46%) and the liver (25%), while the metastases in the 
testis were found only in 0.5% of the cases.130-131 
Transforming Growth Factor Beta  
In mammals, TGF-β super family consists of over 30 structurally related proteins; 
these include 3 forms of TGF-β itself (TGF-β1, TGF-β2, and TGF-β3), 3 forms of 
Activins and over 20 Bone Morphogenetic Proteins (BMPs). These growth factors 
control a large range of cellular behavior132 including regulating cell growth, 
differentiation, and matrix production.133-135 TGF-β is a disulfide-linked homodimeric 
protein which is secreted as part of a complex consisting of two units of the large 
precursor segment of the TGF-β pro-polypeptide linked in a non-covalent association 
with the mature TGF-β dimer.136 This complex is "latent" in the sense that it does not bind 
to TGF-β receptors and therefore cannot exert any biological activities associated with 
TGF-β.136 The release under physiological conditions of active TGF-β from the latent 
complex may be a finely regulated event involving specific proteases.136  
The TGF-β isoforms is initially synthesized as a 75-kDa homodimer known as 
pro-TGF-β. Pro-TGF-β is then cleaved in the Golgi to form the mature TGF-β 
homodimer.137-138 These 25-kDa homodimers interact with latency-associated proteins to 
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form the small latent complex.137-140 In the endoplasmic reticulum, a single latent TGF-β 
binding protein forms a disulfide bond with the TGF-β homodimer to form the large 
latent complex, allowing for targeted export to the extracellular matrix.138-139 After export, 
the large latent complex interacts with fibronectin fibrils and heparin sulfate 
proteoglycans on the cell membrane. Eventually, the large latent complex localizes to 
fibrillin-rich microfibrils in the extracellular matrix, where it is stored until its 
activation;138, 141-142 remaining biologically unavailable until its activation.137-138 Latent TGF-
β is activated by several factors, including proteases,138, 142-143 thrombospondin 1,138, 144 
reactive oxygen species,138, 145 and integrins.138, 146-147 These factors release mature TGF-β by 
freeing it from the microfibri l- bound large latent complex. This occurs through 
liberation from latency-associated proteins, degradation of latent TGF-β binding protein, 
or modification of latent complex conformation.138 
The three mammalian isoforms of TGF-𝛽 are each encoded by different genes and 
share extensive homology (70-80% amino acid sequence identity).94, 148 TGF-β signaling 
begins with the binding of activated TGF-β to specialized receptors on the cells 
membrane. There are three major classes of TGF-β receptor proteins (TGF-β receptors 
types 1-III (abbreviated TβRI, TβRII, and TβRIII, respectively)). TβRI and TβRII are 
serine-threonine protein kinases. TβRII contains extra cellular ligand binding domain, 
and both TβRI/II contain a single transmembrane domain and (Figure 7) a cytoplasmic 




Figure 7: (A) TGF-β type I (TβR-I) and TGF-β type II (TβR-II) are single 
transmembrane protein serine/threonine kinases with two kinase inserts. The extracellular 
domains are rich in cysteine residues. The carboxyl terminal tail is shorter in the TβR-I 
compared to the TβRII. The glycine–serine rich (GS) domain, which regulates the 
receptor activation, and the L45 loop (an exposed nine-amino acid sequence between 
kinase subdomains IV and V), are only found in TβR-I. A comparison of amino acid 
sequences in L45 loop region between activin receptor-like kinase (ALK)1 and ALK5 is 
shown below. The two h strands (h4 and β5) that flank the L45 loop are shown as arrows. 
(B) Endoglin and betaglycan (TGF-β type III receptors or TβR-III) are single 
transmembrane TGF-β accessory receptors that lack an enzymatic motif in their short 
intracellular domains. The percentages of identical amino acids in specific regions of the 
human endoglin and betaglycan are shown. Their cytoplasmic tails contain many serine 
and threonine residues and a putative PDZ domain at the last 3 Carboxy terminal 
residues. Proteolytic cleavage site and potential glycosaminoglycan (GAG) side chains 
that are rich in heparin sulfate and chondroitin sulfate are indicated. (This figure has been 
modified with permission from Miyazono et al. 
 
The kinase domains of the types I and II receptors share only 40% amino acid identity.149 
TGF-β signal transduction requires the formation of a TβRI-TβRII heteromeric 
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complex.150-158 Once the ligand is activated, TGF-β signaling is mediated through SMAD 
and non-SMAD pathways to regulate transcription, translation, microRNA biogenesis, 
protein synthesis, and post-translational modifications.35, 138, 159-160 Although the downstream 
effects of TGF-β are heavily context dependent, its signaling is at least partially 
conserved in many cell types.33, 138 In the canonical pathway, the TGF-β ligand binds to the 
TβRII that recruits the TβRI. These receptors dimerize and autophosphorylate 
serine/threonine residues, allowing for the phosphorylation of SMAD2 and SMAD3 by 
TβRI. The now activated SMAD proteins dissociate from the SMAD anchor for receptor 
activation (SARA) protein, hetero-oligomerize with SMAD4, and translocate to the 
nucleus, interacting with myriad transcriptional co-regulators and other factors to mediate 
target gene expression or repression.35, 138, 161 TβRIII (or betaglycan), a transmembrane 
proteoglycan that binds the TGF-β ligand, whose function is relatively unknown. 
Although TβRIII appears to lack a cytoplasmic signaling domain, it appears to have 
important roles in development, as well as in regulating TβRI and TβRII.138, 162-164 
TGF-β also signals through a number of non-SMAD pathways, including p38 
MAPK, p42/p44 MAPK, c-Src, m-TOR, RhoA, RAS, PI3K/Akt, protein phosphatase 2A 
(PP2A)/p70s6K, and JNK MAPK.138, 160, 165-169 Additionally, two studies have linked 
translational regulation to the cytostatic program governed by TGF-β. The first 
mechanism involves transcriptional activation of the translation-inhibiting protein 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) mediated by the 
SMAD signaling pathway,138, 170 whereas the second relies on catalytic inactivation of the 
translation initiation factor eEF1A1 (eukaryotic elongation factor 1A1) by TβRI.138, 159 
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Both SMAD-dependent signaling and SMAD-independent signaling play multiple roles 
in homeostasis, particularly in the growth and plasticity of epithelial cells. SMAD-
dependent TGF-β signaling induces growth arrest through a number of mechanisms, 
including control over various cyclin-dependent kinase inhibitors.138, 171-174 SMAD-
independent mechanisms of TGF-β–induced apoptosis involve DAXX/HIPK2 and 
transforming growth factor β associated kinase (TAK1)/TRAF6–dependent p38/JNK 
activation.138, 175-176 
Transforming Growth Factor Beta (TGF-β) in Prostate Development and Function  
TGF-β signaling pathway is a key player in metazoan biology, and its 
misregulation can result in tumor development.171 TGF-β made its debut with the rise of 
the vertebrates. TGF-β evolved to regulate the expanding systems of epithelial and neural 
tissues, the immune system, and wound repair.171 Tied to these crucial regulatory roles of 
TGF-β are the serious consequences that result when this signaling pathway 
malfunctions, namely tumorigenesis.171 TGF-β superfamily was discovered in a hunt for 
autocrine factors secreted from cancer cells that promote transformation.22 However, it 
soon became clear that TGF-β and the related BMPs regulate diverse developmental and 
homeostatic processes and are mutated in numerous human diseases. Furthermore, TGF-
β-superfamily members such as activins, Nodal, and growth differentiation factors 
(GDFs) were shown to control cell fate as a function of concentration, thus defining them 
as a key class of secreted morphogens.22 The actions of TGF-β are dependent on several 
factors including cell type, growth conditions, and the presence of other polypeptide 
growth factors.92 The TGF-β pathway has a complicated role in mediating the ability of 
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cells to participate negatively or positively in growth inhibition, proliferation, replication, 
invasion, metastasis, apoptosis, immune surveillance, and angiogenesis.  
TGF-β-superfamily members are highly conserved across animals and comprise 
the largest family of secreted morphogens.22TGF-β elicits context-dependent and cell 
specific effects that often appear conflicting, such as stimulation or inhibition of growth 
(Figure 8), apoptosis or differentiation.92 It is puzzling how such a diverse array of 
responses can result from binding of TGF-β ligand to a receptor complex that activates a 
seemingly straightforward signal transduction scheme dependent on shuttling SMAD 
transducer proteins from the receptor to the nucleus.92 This paradox is reflected in the 
clinic, where in early stage cancers, levels of TGF-β are positively associated with a 




Figure 8: TGF-β in cancer progression:  a.) Normally limits epithelial proliferation. b.) 
Loss of TGF-β inhibition leads to hyperplasia and supports transformation. c.) TGF-β 
growth response can enhances mesenchymal transition leading to invasion. d.) TGF-β 
suppresses T-cell response contributing to escape of immune recognition. e.) TGF-β 
displays angiogenic effects d.) TGF-β enhances extravasation and attachment of tumor 
cells to tissues of distant sites. e.) TGF-β promotes osteoclast response and bone 
remodeling in distant metastasis. 
microenvironment are positively associated with tumor size, invasiveness, and 
dedifferentiation, making TGF-β a useful prognostic biomarker and predictor of 
recurrence after initial or failed therapy.31, 138, 177-179 
TGF-β expression has been studied in nearly all epithelial cancers including, 
prostate, breast, lung, colorectal, pancreatic, and skin cancers.31, 138 TGF-β acts on normal 
prostate epithelial cells and some prostate-cancer cells to inhibit proliferation and induce 
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apoptosis.180-182 TGF-β has also been shown to stimulate E-cadherin expression in 
prostate-cancer cells treated with an mTOR inhibitor.183 Prolonged incubation of cells 
with TGF-β results in the expression of actin-associated proteins (AAP’s), 
tropomyosin,184 and transgelin185 which promote the formation of stress fibers.180 Loss of 
TGF-β is also known to promote the formation of a less organized cytoskeleton. Studies 
have also shown that TGF-β can suppress or induce PTEN expression, depending on the 
Ras/ERK status. A Ras/ERK activated pathway facilitates TGF-β suppression of PTEN 
via a SMAD-4 independent signaling pathway186 however, when Ras/ERK is blocked, 
TGF-β induces PTEN expression through its classical SMAD-dependent pathway and 
stimulates a tumor suppressive response.183, 187 Such a switch is echoed in pancreatic 
carcinoma cells, where both activated Ras and PI3K cause TGF-β to down regulate E-
cadherin expression through a SMAD-independent pathway.188 In colorectal cancer higher 
TGF-β1 protein expression is associated with increasing T-stage and metastatic disease, 
indicating that TGF-β1 is of importance in tumor progression.177 Plasma TGF-β levels are 
markedly elevated in men with prostate cancer metastatic to regional lymph nodes and 
bone.179 In men without clinical or pathologic evidence of metastases, the preoperative 
plasma TGF-β level is a strong predictor of biochemical progression after surgery, 
presumably because of an association with occult metastatic disease present at the time of 
radical prostatectomy.179 
Because perturbation of the TGF-β signaling network has a variety of tumorigenic 
effects, its mechanisms must be studied further to identify novel points of convergence 
with other pathways and maximize both the clinical efficacy and tumor specificity of 
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future therapies. Through investigation of the TGF-β pathway and its relationship with 
other oncogenic factors in the tumor microenvironment, additional strategic points of 
convergence can be identified and exploited as a means to prevent or reverse tumor 
progression.138 As was already discussed, prostate cancer remains an important clinical 
problem, with current therapies being far from adequate, so it is essential to develop new 
therapeutic approaches. Understanding of the integration of TGF-β pathway known to be 
involved in prostate cancer pathophysiology may be central to the development of 
improved pharmacological treatments. A dual role of TGF-β in cancer has long been 
noted, but its mechanistic basis, operating logic, and clinical relevance have remained 
elusive. What causes TGF-β signaling to be altered in cancer? What steps in tumor 
progression may benefit from a faulty TGF-β pathway? When does TGF-β act as a 
metastatic signal? And, most importantly, how can any of this knowledge be used to treat 
prostate cancer? 
Activator Protein-1 (AP-1) 
The primary control of eukaryotic gene expression occurs at the level of 
transcription where genes may be regulated in response to a specific signal or in a 
particular tissue-type.66, 189 Transcriptional control of a gene involves the binding of 
regulatory proteins or transcription factors to short, cis-acting DNA sequence elements 
located within and near the promoter of a gene.66, 190-192 Following the binding of 
transcription factors, the activity of RNA polymerase is modulated in either a positive or 
negative manner at the start site of transcription.66 There are several types of DNA 
sequence sites to which transcription factors will bind, these include: promoter elements 
situated close to or at the start site of transcription which are essential for activation or 
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significant levels of transcription;66, 193-195  regulatory elements situated close to the general 
promoter region functioning in an orientation-independent manner;66, 195-198 and 
enhancer/repressor elements located at a distance from the transcription start site which 
increase or decrease the rate of transcription.66, 199-200  
AP-1 Family members 
 AP-1 is a collective term referring to dimeric transcription factors composed of 
JUN, FOS or ATF (activating transcription factor) subunits that bind to a common DNA 
site, the AP-1-binding site. The consensus binding site for AP-1 was identified as the 
palindromic sequence 5’ TGA/TCA 3’, which was found to be responsive to the phorbol 
ester, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) referred to as the TPA-responsive 
element (TRE).66, 201 As the complexity of our knowledge of AP-1 factors has increased, 
our understanding of their physiological function has decreased.114 AP-1 is an important 
and well-studied transcription factor; the protein components of this transcription factor 
are encoded by a set of genes known as “immediate-early” (IE) genes.66, 202 IE genes 
couple cytoplasmic biochemical changes, arising from the binding of stimulatory agents 
to cell-surface receptors to mediate specific cell responses.66 AP-1 was initially identified 
as a DNA-binding activity in HeLa cell extracts that bound to cis-elements within the 
promoter and enhancer sequences of the human metallothionein IIA gene and simian 
virus 40.66, 203  
The transcription factor AP-1 was subsequently found to be comprised of protein 
dimers, containing the gene products of members of the JUN (JunD, cJUN, JUNB) and 
FOS (FosB, cFos, Fra1, Fra2) gene families.66, 204-206  The JUN protein members form 
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homo- and heterodimeric complexes within their own gene family66, 207-208 and with the 
protein members of the FOS gene family.66, 89, 209-211 Unlike the JUN proteins, FOS is unable 
to form homodimers and must heterodimerize with JUN proteins in order to 
transcriptionally activate AP-1-containing promoter constructs in cells.66, 212-213 
Structure  
 The AP-1 family of transcription factors is a basic leucine zipper (bZIP) dimeric 
protein complex of structurally and functionally related members of JUN, FOS, ATF and 
musculoaponeurotic sarcoma (MAF) protein families. The basic region or DNA binding 
domain (DBD) of bZIP proteins contains positively charged amino acid residues required 
for DNA binding activity85 (Figure 9). The leucine-zipper domain (LZD), located 
immediately downstream of DBD, contains a heptad repeat of leucine residues. LZD 
mediates the dimerization of proteins, bringing two DBDs into juxtaposition, thereby 
facilitating the interaction of protein dimers with DNA. Although LZD and DBD are 
highly conserved among all AP-1 proteins, their amino (NH2) - and carboxy (COOH)-




Figure 9: Schematic diagram showing the modular structures, dimerization and DNA 
binding properties of JUN and FOS proteins. A) the location of various modules is 
indicated. TAD, transcription-activating domain; LZD, leucine-zipper domain; DBD, 
DNA binding domain; N, amino terminus; C, carboxyl terminus. B) LZD mediates the 
dimerization of proteins bringing two DBDs into juxtaposition, thereby facilitating the 
interaction of protein dimers with DNA. ATF, activation transcription factor; TRE, 12-O-
tetradecanoylphorbol-13-acetate (TPA)-responsive element; CRE, cyclic AMP-
responsive element. Note that CRE has an extra base (underlined) compared with TRE. 
 
The JUN proteins contain the transactivation domain (TAD) at their NH2-terminal 
region, whereas FOS members, except Fra1 and Fra2, possess TADs at their NH2- and 
COOH-terminal regions (Figure 9). In many tumors these non-transforming FOS 
proteins, especially Fra1 and Fra2, might be involved in the progression of many tumor 
types.87, 214 The JUN gene family is similar to each other in their gene and protein 
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structure, particularly in the DNA-binding domain and the leucine zipper regions where 
there is 75% amino acid homology with the JUN Family.66, 215 The cFos protein is 
evolutionally well-conserved, as its protein sequence retains an overall homology of 97, 
94 and 79% between rat and mouse, rat and human, and mouse and chicken cFos 
proteins, respectively.66, 216 In addition to cFos other related genes have been identified. 
FosB and its naturally truncated form ΔFosB (missing the C-terminal 101 amino acids of 
FosB),217 Fos-related antigen-1 (Fra-l), and Fos-related antigen-2 (Fra-2), together with 
cFos make up the FOS gene family.66, 211, 217-220 These genes are structurally-related to cFos 
in terms of having the same number of exons and introns; however, the size of the 
untranslated regions of the genes is variable. The amino acid sequence between each 
protein is also conserved, particularly in the basic DNA and leucine zipper regions.66, 219 
Similarly to cFos, the protein products of other members of the FOS gene family are 
unable to bind to DNA individually, and require dimerization with a JUN protein to form 
a functional AP-1 complex.66, 89, 210-211, 217 However, despite their homology, these proteins 
display different transcriptional activity.221  
Functions  
 AP-1 is an inducible transcription factor,66 that may regulate different target genes 
and thus execute distinct biological functions.114 Various agents have been shown to 
induce the expression of the FOS gene family; agents such as serum, growth factors, 
neurotransmitters, calcium, phorbol esters, metal ions, UV light and cAMP.66 The 
decision if a given AP-1 factor is positively or negatively regulating a specific target gene 
is made upon abundance of dimerization partners, dimer-composition, post-translational 
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regulation, and interaction with accessory proteins.222 In vitro studies have shown that 
JUN/FOS heterodimers are more stable and have a stronger DNA binding activity than 
JUN homodimers.85, 223 The reason for this binding specificity amongst bZIP families can 
be attributed to the amino acid combination between the leucine residue repeats within 
the leucine zipper region.66, 224 cFos has a highly acidic leucine zipper with a large net 
negative charge at neutral pH thus a homodimer formation would not be favored owing to 
general electrostatic repulsions between the monomer FOS proteins.66, 224 In addition, the 
acidic residues important for specificity are aligned along one face of the helix, causing 
intra-helical destabilization. The cJun leucine zipper has a more diffuse, net positive 
charge, allowing a JUN homodimer to form. However, the interaction of Jun proteins is 
not as stable as a FOS/JUN dimer. As the FOS and JUN monomers are of opposite 
charge, they may form a more stable heterodimer together as the interhelical component 
of the electrostatic destabilization is relieved.66, 224 Different FOS/JUN complexes also 
have different affinities for AP-1 sites, and this is partly attributed to different DNA 
sequences around the core AP-1 site.66, 223  
AP-1-regulated genes include important regulators of invasion, and metastasis, 
proliferation, differentiation and survival, genes associated with hypoxia and 
angiogenesis.87, 113, 115 Many oncogenic signaling pathways converge at the AP-1 
transcription factor complex. The specific influence of a specific AP-1 protein on a 
promoter depends on the dimer partners, the promoter architecture as well as other 




Activator Protein-1 in Cancers and Prostate Cancer 
As stated earlier, DNA binding is a necessary prerequisite of transactivation; the 
expression of different proteins of the JUN and FOS family is crucial for the activation of 
downstream genes regulated by AP-1. AP-1 is known to control the expression of several 
target genes that regulate cell cycle (cyclin D, p16), differentiation (myogenin, 
involucrin), cell survival (Bcl-2, Bcl-xL, FasL), growth factors (VEGF), and cell 
adhesion (VCAM, EDAM-1) and angiogenesis/invasion (MMP’s, uPA, osteopontin, 
CD44).82 In the prostate, various members of the AP-1 family have been implicated in the 
actions of androgen receptors.225 Activation of cJun has been shown to play a role in the 
development of androgen independent prostate cancer; the overexpression of cJun has 
been shown to inhibit the expression and function of androgen receptor in human prostate 
cancer cells.226 The expression of interleukin-6, which increases in hormone refractory 
prostate cancer cell, is dependent on constitutive activation of Fra1 and JunD.227 Jun N-
terminal Kinases (JNKs), which phosphorylate and activate AP-1 proteins have been 
shown to be involved in proliferation and tumor growth and survival of prostate cancer 
cells.225, 228-229 These studies have underlined the importance of AP-1 proteins in the 
development and function of prostate cells and a change in the relative abundance and/or 
activities of specific proteins may be involved in development and maintenance of 
prostate cancers. However, in spite of these studies, the role of individual AP-1 family of 






Activator Protein-1 in TGF-β Signaling 
AP-1 transcription factors contribute to various TGF-β biological responses.230 
The promoters of TGF-β1-reponsive genes like plasminogen activator inhibitor-1 (PAI-1) 
and cJun contain AP-1 binding sites. Mutation of these AP-1 binding sites which impairs 
binding of the AP-1 complex inhibits transcriptional activation of these promoters by 
TGF-β1.231-232 SMAD proteins possess DNA-binding activity, but the SMAD4-RSMAD 
complexes must associate with additional DNA-binding cofactors in order to achieve 
binding with high affinity and selectivity to specific target genes. These Smad partners 
are drawn from various families of transcription factors, such as the forkhead, homeobox, 
zinc-finger, bHLH, and AP1 families.171, 233-234 These findings suggest that SMAD proteins 
and AP-1 complex synergize to activate the TGF-β1-responsive promoters.235 Naso et al 
2003 showed that JunB is up-regulated by TGF-β-SMAD signaling and may contribute to 
the TGF-β-induced EMT and fibrotic responses.236 Recent studies indicate that SMAD-3 
directly binds cJun and cFos of the AP-1 complex and that both SMAD-3 and SMAD-4 
bind all three Jun proteins.53 Studies also show that TGF-β1 activates SMAD proteins and 
AP-1 complex (JunD: FosB) and that over-expression of their dominant negative forms 
inhibits TGF-β1 dependent apoptosis.235 Over expression of FosB enhances SMAD-
dependent transcription of TGF-β1 responsive reporter. JunD: FosB recruits SMAD-
3:SMAD-4 to from AP-1:SMAD complex that binds to the AP-1 binding site, 12-O-
tetradecanoyl-13-acetate- responsive gene promoter element.235 These studies show that 
both SMAD proteins and AP-1 complexes play a critical role in TGF-β1-dependent 
apoptosis. Our data has shown that TGF-β1 transiently induces mRNA and protein 
expression levels of AP-1 components in DU145 and PC3 prostate cancer cell lines, but 
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the role of these inducted AP-1 components in TGF-β1 dependent growth, proliferation, 
migration, and invasion remains unknown. 
AP-1 Proteins in TGF-β signaling in Cancers and Prostate Cancer 
Jun family members (c-Jun, JunB, and JunD) were expressed at different levels 
and responded differentially to TGF-β treatment. TGF-β effects on JunD protein levels, 
but not mRNA levels, correlated with its effects on cell proliferation. TGF-β induced 
significant reduction in JunD protein in RWPE-1 and DU145 cells but not in PC3 cells. 
Selective knockdown of JunD expression using siRNA in DU145 and PC3 cells resulted 
in significant reduction in cell proliferation, and forced overexpression of JunD increased 
the proliferation rate.50  Previously published work in our lab shows that overexpression 
of c-Jun and JunB decreased the proliferation rate in DU145 cells. Further studies showed 
that down-regulation of JunD in response to TGF-β treatment is mediated via the 
proteasomal degradation pathway.50 Thus concluding, specific Jun family members exert 
differential effects on proliferation in prostate cancer cells in response to TGF-β, and 






MATERIALS AND METHODS 
Chemical and Reagents 
Recombinant human TGF-β1 (Catalog # HEK293 100-21) was purchased from 
Peprotech (Rocky Hill, NJ). The antibodies against FosB (Catalog# 2251S), cFos 
(Catalog # SC-52), Fra1 (Catalog # SC-605), and Fra2 (Catalog # SC-604) were 
purchased from Santa Cruz Biotechnology, Inc.  (Dallas, TX). The anti-β-Actin (Catalog 
# A5441) antibody was purchased from Sigma-Aldrich (St. Louis, MO). The anti-mouse 
and anti-rabbit immunoglobulins coupled with horseradish peroxidase (IgG-HRP) were 
obtained from Promega (Madison, WI). Cell lysis buffer was purchased from Cell 
Signaling (Danvers, MA). TRIzol was purchased from Invitrogen (Carlsbad, CA).  
Human Prostate Cell Lines and Treatments 
All cell lines were obtained from American Type Culture Collection. These 
include immortalized prostate luminal epithelial cell line (RWPE1) and prostate cancer 
cell lines (LNCaP, DU145, and PC3). 
Expression of FOS family members: Prostate cells (RWPE1, LNCaP, DU145 and PC3) 
were cultured using established procedures.151, 157, 237 To determine the basal expression of 




a density 1.0 X 106 cells/dish in a 10 cm petri dish in the appropriate growth media and 
cultured at 37°C for 48 h. After 48 h, the cells were washed with ice-cold phosphate 
buffered saline (PBS) and lysed in cell lysis buffer containing 20 mM Tris-HCl (pH 7.5), 
150 mm NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, and 1 X 
protease inhibitor cocktail (Calbiochem, San Diego, California). Protein concentrations 
were determined by the Lowry HS assay using the Bio-Rad DC Protein Assay kit (Bio-
Rad Laboratories, Inc., Hercules, CA.) according to the instructions provided by the 
manufacturer. The total RNAs were isolated from parallel experiments and were also 
used for RT-PCR as described below. To determine the effects of TGF-β1 on FosB, cFos, 
Fra1, and Fra2 expression, prostate cancer cells were seeded in six-well plates at a 
density of 3.0 X 105 cells per well.  Before each experiment DU145 and PC3 cells were 
incubated with media supplemented with 1% serum for 2 h followed by treatment with 
different doses of TGF-β1 (0, 1, 5, 10 ng/mL) for specific time periods.  RNA and 
proteins were isolated and quantified.  
RNA isolation, cDNA synthesis, and RT-PCR 
Total RNAs were isolated from prostate cells using TRIzol (Invitrogen, Carlsbad, 
CA.) and the resulting RNA samples were quantified by optical density reading at 260 
nm as described previously.238 Total RNAs (2 µg) were reverse transcribed in a 50 µl 
reaction mixture containing 0.5 mM dNTP (Fisher Scientific, Pittsburgh, PA), 0.5 mM 
dithiotreitol (Bio-Rad, Hercules, CA), 0.5 µg of oligo dT,  and 400 U of M-MLV Reverse 
Transcriptase (Promega, Madison, WI.) at 37°C for 1.5 h.  The reaction was terminated 




performed to detect mRNA levels of FosB1, FosB2, cFos, Fra1, Fra2, and L-19. The PCR 
mixture was composed of 0.1 mM deoxynucleotide triphosphates, 0.5 U Taq DNA 
polymerase, 10X PCR Buffer with 3 mM MgCl2 and 25 pM of the specific primers in a 
total volume of 15 µL. Primer information and the size of specific amplicons for 
individual genes are shown in Table 1. L-19 (a ribosomal protein) was used as a loading 
control. RNA samples processed without RT and PCR amplified were used as negative 
controls. Amplification was performed at 1, initial denaturant 94°C for 2 min; 2, 94°C for 
15s; 3, 58°C for 15s; 4, 72°C for 30s, 5, repeating steps 2 and 4 for 35 cycles for FosB1, 
FosB2, cFos, Fra1, Fra2, and L-19; 5, final extension 72°C for 2 min. The PCR products 
were separated on 1.0-2.0% agarose gels, and viewed under UV.  
Western Blot Analyses 
Total cellular proteins were prepared from different prostate cell lines and were 
analyzed by Western blot as described previously.238 Briefly, cell lysates were mixed with 
Laemmeli’s buffer (62.5 mM Tris, pH 6.8, 2% SDS, 5% β–mercaptoethanol, and 10% 
glycerol). Individual samples containing 30–35 µg protein were subjected to SDS-PAGE 
in 10% gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore 
Corp., Bedford, MA). After blocking the membranes with 5% fat free milk in TBST (50 
mM Tris, pH 7.5, containing 0.15 M NaCl, and 0.05% Tween–20) (cFos, Fra1, Fra2) or 
5% bovine serum albumin (BSA) in TBST (FosB), for 1 h at room temperature, the 
membranes were incubated with appropriate dilutions of specific primary antibodies 
(1:500 for Fos proteins and 1:5000 for β-actin) overnight at 4°C. After washing, the blots 
were incubated with secondary anti-rabbit (for FOS proteins) and anti-mouse (for β-actin) 




Scientific Inc., Rockford, IL), and placed inside the Syngene PXi/PXi Touch darkroom 
imaging (high resolution, multi-application image analysis systems) (Frederick, MD) 
according to the manufacturer’s directions and the density of specific protein bands were 
determined using ImageJ image processing and analysis software and values were 
normalized using β-actin. 
Immunofluorescence of FosB 
PC3 cells were seeded at a density of 8.0 x 104 cells/well into six-well plates 
containing sterile glass coverslips. The cells were incubated at 37°C and allowed to attach 
for 48 h. The media were replaced with fresh media containing 1% FBS for 2 h before 
treatment with TGF-β1 (10 ng/ml) for 4 h. At the end of the treatment, media were 
aspirated and cells were fixed in 3.7% paraformaldehyde for 20 minutes at room 
temperature. The fixative was aspirated and cells were rinsed three times with 1.0 ml 1X 
PBS and permeabilized using 0.1% Triton at room temperature. The cover slips were 
transferred to an aluminum wrapped 20 cm Petri dish and outlined using a hydrophobic 
marker.  The cells on the cover slips were blocked in blocking buffer containing 10% 
normal goat serum in 1X PBS for 1 h. Blocking solution was aspirated and primary 
antibody (1:1000) for FosB was added overnight at 4°C in 1X PBS with 2% normal goat 
serum. After washing 5 times in 1X PBS for 10 minutes each, secondary antibody 
containing green fluorochrome (Alexa Fluor 488 goat anti-rabbit IgG, Life Technologies, 
Carlsbad, CA) was added at room temperature for 1 h in 1X PBS (light sensitive).  After 
washing, DAPI (3 µg/ml) was added to cells for 20 minutes at room temperature to stain 
the nuclei. The cells were rinsed and the cover slips were then mounted on slides.  Slides 




florescence microscope. Images were captured using 40 X magnification with an 
Axiovision camera of a Carl Zeiss zoom inverted florescence microscope (Carl Zeiss, 
Thornwood, NY). 
Transfections 
Transfection with FosB siRNA 
To knockdown endogenous FosB expression, DU145 and PC3 cells were seeded 
in six-well plates at the density 1.5 X 105 cells per well in 1.0 mL antibiotic-free normal 
growth medium supplemented with 5% FBS. The cells were cultured at 37°C to 60-80% 
confluence. Control (scrambled) and FosB specific siRNAs were transfected into DU145 
and PC3 cells according to the manufacturers’ instructions.  Briefly, transfection complex 
were mixed together in a 1:1 ratio (2.5 µL for FosB) of siRNA to transfection reagent in 
200 µL of antibiotic-free normal growth medium. The mixture was allowed to incubate at 
room temperature in the dark for 20 minutes. During this time the cells were washed once 
with 1 mL of siRNA transfection medium, after which  the antibiotic-free medium was 
mixed with 1% FBS and added to the transfection reagent mixture. The transfection 
reagent siRNA duplex was overlaid onto the washed cells, and the cells were incubated 
overnight. The medium containing the transfection complex was replaced with complete 
medium containing 5% FBS and incubated for 48 h. Cells were trypsinized (0.25% 
Trypsin/ 2.21 mM EDTA) for 1 minute and trypsin was neutralized with 3.0 mL of 
complete medium. Cells were centrifuged at 1000 RPM 4°C for 5 minutes and re-plated 






Transfection with cFos, Fra1 and Fra2 siRNAs 
To knockdown endogenous cFos, Fra1 and Fra2 expression, DU145 and PC3 
cells were seeded in six-well plates at the density 1.5 X 105 cells per well in 1.0 mL 
antibiotic-free normal growth medium supplemented with 5% FBS. The cells were 
cultured at 37°C to 60-80% confluence. Control (scrambled) and cFos, Fra1 and Fra2 
specific siRNAs were transfected into DU145 and PC3 cells according to the 
manufacturers’ instructions.  Briefly, transfection complex were mixed together in a 1:1 
ratio (6 µL for cFos, Fra1 and Fra2) of siRNA to transfection reagent in 200 µL of 
antibiotic-free normal growth medium. The mixture was allowed to incubate at room 
temperature in the dark for 20 minutes cells were treated as previously described above. 
After being transiently transfected to silence cFos, Fra1 and Fra2 DU145 and PC3 cells 
were used in cell proliferation and migration assays. 
Transfection with cJun siRNAs 
siRNA was used to  knockdown endogenous cJun expression, PC3 cells were 
seeded in six-well plates at the density 1.5 X 105 cells per well in 1.0 mL antibiotic-free 
normal growth medium supplemented with 5% FBS. The cells were cultured at 37°C to 
60-80% confluence. Control (scrambled) and cJun specific siRNAs were transfected into 
PC3 cells according to the manufacturers’ instructions.  Briefly, transfection complex 
were mixed together in a 1:1 ratio (6 µL for cJun) of siRNA to transfection reagent in 200 
µL of antibiotic-free normal growth medium. The mixture was allowed to incubate at 
room temperature in the dark for 20 minutes cells were treated as previously described. 





Cell Proliferation Assays 
MTT Assays 
After transient transfection, the cells were counted and seeded into 96-well plates 
at a density of 5 X 103cells/well and treated with 10 ng/mL of TGF-β1 in the presence of 
1% FBS for 72 hours. Cell viability was measured using 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay. MTT assays were performed using Cell 
Titer 96 Non-radioactive Cell proliferation assay (Promega, Madison, WI) following the 
manufacturer’s instructions.  
MTS Assays 
After transient transfection, the cells were counted and seeded into 96-well plates 
at a density of 5 X 103cells/well and treated with 10 ng/mL of TGF-β1 in the presence of 
1% FBS for 72 hours. Cell viability was measured using 3-(4, 5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl) -2-(4-sulfophenyl)-2H-tetrazolium inner salts (MTS) assay. 
MTS assays were performed using Cell Titer 96 AQueous One Solution Cell proliferation 
assay (Promega, Madison, WI) following the manufacturer’s instructions.  
Total Cell Number Assays 
After DU145 and PC3 prostate cancer cells were transiently transfected to silence 
the Fos family proteins (cFos, Fra1 and Fra2) cells were trypsinized using 400 µl of 
trypsin and neutralized using 3000 µl of MEM and centrifuged at 5000 rpm, 4ºC for 5 
minutes to remove trypsin. The cells were then re-suspended in 1000 µl MEM in a 1.5 µl 
Eppendorf tubes as previously described and counted using the hemocytometer. Media 
was gently pipetted to ensure the cells are evenly distributed. Before the cells have a 




into both chambers on the hemocytometer glass slide underneath the coverslip, allowing 
the cell suspension to be drawn out by capillary action. An Oxioskop 2 Plus Ziess light 
microscope was used to focus on the grid lines of the hemocytometer with a 10X 
objective. Cells were then counted using a hand tally counter. A counting system was 
employed whereby cells were only counted when they are set within a square or on the 
right-hand or bottom boundary line.  The hemocytometer was moved to the next set of 16 
corner squares and carry on counting until all 4 sets of 16 corners are counted. This was 
done twice for each treatment allowing a total of 8 sets of 16 squares per treatment. The 
average of each set of 16 corner squares were taken and multiplied by 10,000 (104). Each 
treatment was done at least three times using different cell preparation each time and 
average displayed in a representative figure that showed the number of cells represented 
on the Y axis and varying treatments on the X axis. 
Cell Migration Assays  
After the transfections, in vitro cell migration assays were performed using 24-
well transwell inserts (8 µm) as previously described.239-240 Chemoattractant solutions were 
made by diluting TGF-β1 (10 ng/ml) or EGF (10 ng/ml) into MEM for DU145 and PC3 
cells supplemented with 0.2% BSA.  The results were expressed as migration index 
defined as: the average number of cells per field for test substance/the average number of 
cells per field for the medium control. The experiments were conducted at least three 
times using independent cell preparations. 
Cell Invasion Assays 
After transfection, the invasive behavior of PC3 cells was measured using the BD 




NJ) were coated with 50 µl of 1:4 Matrigel/Medium dilutions (BD Sciences, San Jose, 
CA) and allowed to solidify at 37°C for 1 h.  Cells were resuspended (5.0 X 104 cells/ml) 
in MEM and 0.1% FBS and 500 µl of cell suspension was added to each insert. 
Chemoattractant solutions were made as described above with TGF-β1 and EGF into 
MEM supplemented with 0.1% FBS. Matrigel and non-invading cells were removed by 
scrubbing. Invading cells in the membrane were fixed in 3.7% paraformaldehyde and 
stained with DAPI. Pictures were taken from five different fields for average number of 
invading cells to be determined. The results were expressed as an invasive index defined 
as: the average number of cells per field for test substance/the average number of cells 
per field for the medium control. The experiments were conducted at least three times 
using independent cell preparations.  
Co-immunoprecipitation  
 3.0 X 106  PC3 cells were plated in 10 cm petri dish with total volume of 10 ml 
MEM supplemented with 5% FBS and allowed to incubate overnight at 37ºC. The MEM 
was then aspirated and replaced with fresh MEM supplemented with 1% FBS for 2 hours 
before treatment. The cells were then treated with 10 ng/ml of TGF-β1 for 4 hours and 
then harvested under non-denaturing conditions. Briefly, MEM was removed and cells 
were rinsed once with ice cold 1X PBS. The PBS was removed and replaced with ice 
cold cell lysis buffer (containing 20 mM Tris-HCl (pH 7.5), 150 mm NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, and 1 X protease inhibitor cocktail 
(Calbiochem, San Diego, California)) and placed on ice for 10 minutes. The cells were 




were then sonicated three times 5 seconds each whilst still on ice. Cells suspension was 
then centrifuged for 10 minutes at 14,000 X g, 4ºC and the supernatant was transferred to 
a new tube. The cell lysates were pre cleaned to reduce nonspecific binding of Protein by 
combining 400 µl of cell lysates with 40 µl of protein A sepharose beads and incubation 
at 4ºC for 45 minutes without rotation shaker. The cells lysates were then spun for 10 
minutes at 4ºC and the supernatant transferred to a fresh tube. FosB primary antibody was 
added (1:50 dilution) to 400 µl of the cell lysates and incubated with gentle rocking 
overnight at 4ºC. 40 µl of protein A sepharose beads were added to cell lysates and 
incubated overnight at 4ºC with gentle shaking. Tubes containing cell lysate and protein 
A were then centrifuged at 4ºC for 30 seconds. The supernatants were transferred to fresh 
tubes. The pellets were washed 5 times with 500 µl of 1X cell lysis buffer and kept on ice 
during washes. The pellets were re-suspended in 40 µl of 2X SDS sample loading buffer, 
vortexed and the micro centrifuged for 30 seconds at 4ºC. The samples were then heated 
95-100ºC for 5 minutes and centrifuged for 1 minute at 14,000 X g. After which the 
samples were loaded on SDS-PAGE gel and analyzed using Western Blot. 
Statistical analysis 
All experiments were repeated at least three times using a different cell 
preparation. ANOVA, Duncan’s modified multiple range and Student-Newman-Keuls 









Expression of FOS family members in prostate cancer cell lines 
We initially screened four human prostate cell lines, RWPE1 (normal prostate 
epithelial cells), LNCaP, DU145 and PC3 (prostate cancer cell lines) for expression of 
FOS family members. Levels of mRNA for FosB, cFos, Fra1 and Fra2 were determined 
using RT-PCR, with L-19 used as control (Figure 10A). Fra2 mRNA was robust in all 
four cell lines, Fra1 and FosB mRNA were highly expressed in all cell lines except in 
LNCaP, which also had very low mRNA levels of cFos ΔFosB was highly expressed in 
all cells with only moderate expression in RWPE1 cells (Figure 10A). Western blot 
analyses was performed to determine the relative protein abundance of FosB, cFos, Fra1 
and Fra2 (Figure 10B). Fra1 protein levels were very low in all prostate cancer cell lines 
(LNCaP, DU145, and PC3) with slightly higher levels in RWPE1 cells (Figure 10B). 
Fra2 protein levels were relatively high in RWPE1, DU145 and PC3 but were not 
detectable in LNCaP cells. cFos showed moderate expression in RWPE1, DU145 and 
PC3 cells but was very low in LNCaP cells. FosB and ΔFosB protein levels were high in 
RWPE1 and PC3 cells but low to moderate in LNCaP and DU145 cells respectively 





Figure 10: FOS family basal expression- Steady state mRNA levels of FOS (FosB, cFos, 
Fra1, and Fra2) mRNA and protein expression. A, Total RNA’s were isolated and semi 
quantitative RT-PCR was performed to determine the mRNA levels of FosB, cFos, Fra1, 
and Fra2 in prostate cells. L-19 was used as an internal control. B, western blot analysis 
of FosB, cFos, Fra1, and Fra2 in prostate cells. β-actin was used as a loading control. 
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TGF-β1 effects on FOS protein expression and nuclear accumulation in prostate 
cancer cells 
DU145 and PC3 cells were treated with exogenous TGF-β1 (10 ng/ml) for 0, 1, 2, 
and 8 h. TGF-β1 induced an increase in the mRNA levels of FosB (P<0.05) in both cell 
lines but had little effect on the mRNA levels of the other FOS family members (Figure 
11A). At the protein levels, TGF-β1 induced an increase in the levels of FosB (P<0.05) 
protein in both cell lines and an increase in Fra2 (P<0.05) protein levels was observed 
only in PC3 cells. TGF-β1 had no effect on the levels of cFos and Fra1 in both cell lines 
(Figure 11B). Spot densitometry analysis confirmed TGF-β1 effects on FosB and Fra2 
protein levels in DU145 and PC3 cells in a time-dependent manner (Figure 11C). TGF-
β1 induction of FosB was dose dependent (Figure 11D). Immunofluorescence of FosB in 
PC3 cells showed that treatment with TGF-β1 induced increased expression and nuclear 
localization of FosB (Figure 11E).  Inhibition of TGF-β receptors as well as Smad3 
abrogated TGF-β1 ability to increase FosB protein expression (Figure 11F); however 
inhibitors against PI3K and MAPK had no effect on TGF-β1 ability to increase FosB 




Figure 11: A, RT-PCR analysis of FosB, cFos, Fra1, and Fra2 mRNA levels in DU145 
and PC3 prostate cancer cells after exposure to exogenous TGF-β (10 ng/mL) for 
different times. B, western blot analysis of FosB, the FosB antibody used recognizes both 
full length FosB (higher molecular weight band) and ΔFosB (lower molecular weight 
band), cFos, Fra1, and Fra2 protein levels DU145 and PC3 prostate cancer cells after 
exposure to exogenous TGF-β1 (10 ng/mL) for different times. C, Band density analysis 
of FosB and Fra2 in DU145 and PC3 cells after treatment with TGF-β1 for 2 and 8 hours. 
Each band density was normalized by density of β-actin bands. Each bar represents the 
Mean ± SD from 3 independent experiments. “a and b” denote significant differences 






Figure 11: D, The Dose dependent effects of TGF-β1 on expression of FosB; Western 
blot analysis of FosB in prostate cancer cells DU145 and PC3 after treatment with 
varying concentrations of exogenous TGF-β1 (0, 1, 5, 10 ng/mL) for 4 hours. E, 
Immunofluorescence, TGF-β1 activation of FosB in PC3. Cells were treated with 
exogenous TGF-β1 (10 ng/mL) for 0, and 4 hours. F, DU145 and PC3 cells were treated 
with inhibitors for TGF-βRI/II, Smad3, PI3K and MAPK.   
FosB knockdown on TGF-β1-mediated cell proliferation, migration and invasion 
Next we determined the role of FosB in TGF-β1-induced cell proliferation, 
migration and invasion in prostate cancer cells. A transient knock down of FosB was 
carried out using siRNA specific to FosB, followed by a MTT proliferation (Figure 12A, 
B), trans-well inserts migration assays (Figure 13A, B) and Matrigel invasion assays 
(Figure 14). Knock down of FosB had no effect on cell proliferation in DU145 and PC3 
cells (Figure 12 A, B) however; there was a significant decrease (P<0.05)  in cell 
migration (DU145, PC3) and cell invasion (PC3: P<0.05)  in response to TGF-β1 and 
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EGF in these cells (Figure 13A, B and Figure 14). Our data also suggests that FosB 
knockdown reduced both TGF-β1-and EGF- induced cell invasion but had no significant 
effect on the basal invasive potential of these cells (Figure 14). 
 
Figure 12: Effects of FosB knock down on TGF-β1-induced cell proliferation- DU145 
and (A) PC3 (B) cells were transfected with siRNA to transiently silence FosB followed 




Figure 13: Effects of FosB knock down on cell migration- Prostate cancer cells DU145 
(A) and PC3 (B) were pretreated with siRNA against FosB for 72 hours. Western blots 
were used to confirm knock down of endogenous FosB (inserts). DU145 and PC3 cells 
were pretreated with siRNA against FosB, followed by treatment with 10 ng/mL of 
exogenous TGF-β1 and 10ng/ml EGF migratory behavior were measured using transwell 
insert migration assay. Each bar represents Mean ± SEM from three independent 
experiments. Different letters designate statistically significant (P<0.05) differences 




Figure 14: Effects of FosB knock down on cell invasion -PC3 cells were pretreated with 
siRNA against FosB, followed by treatment with 10 ng/mL of exogenous TGF-β1 and 10 
ng/ml EGF invasive behavior were measured using and Matrigel in vitro invasion assay. 
Insert shows western blot used to confirm FosB knock down. Each bar represents Mean ± 
SEM from three independent experiments. Different letters designate statistically 
significant (P<0.05) differences among different treatments. 
FOS Family Members role in Prostate Cancer Cell Growth and Proliferation 
 After finding out that FosB increased protein expression in DU145 and PC3 
prostate cancer cells in response to TGF-β1 stimulation had no effect on prostate cancer 
cell proliferation; the other FOS family members (cFos, Fra1, and Fra2) were transiently 
silenced using siRNA specific to each family. This was followed by cell count and MTS 
proliferation assay. Our results indicated that transiently silencing cFos and Fra1 had no 
effect on cell number in DU145 prostate cancer cells (Figure 15A). Our data also showed 
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that cFos knock-down increased (P<0.05) cell number in PC3 cells and Fra1 knock down 
had no effect on cell number in these cells (Figure 15B). Our data showed that TGF-β1 
increases the expression of Fra2 (Figure 11B, C) protein expression in PC3 prostate 
cancer cells only. In order to determine the role of this increased Fra2 protein expression 
Fra2 was transiently silenced in both DU145 and PC3 prostate cancer cells followed by 
cell count and MTS proliferations assays. The cell count data (not shown) indicated that 
Fra2 knock-down in PC3 cells results in decrease in cell number, MTS data supported the 
data seen by cell counting showing that Fra2 knock-down in PC3 cells resulted in 
decreased (P<0.05) cell proliferation (Figure 16B). On the other hand knock-down of 
Fra2 had no effect on cell count or cell proliferation in DU145 cells in the presence or 
absence of TGF-β1 (Figure 16A). Our data also showed that transiently knocking down 





Figure 15: A) DU145 cells were transfected with siRNA to transiently silence cFos and 
Fra1 followed by an in vitro proliferation assay. Insert western blot image confirming 
cFos and Fra1 knock down. B) PC3 cells were transfected with siRNA to transiently 
silence cFos and Fra1 followed by an in vitro proliferation assay. Different letters 
designate statistically significant (P<0.05) differences among different treatments. Insert 




Figure 16: A) DU145 cells exposed to siRNA specific for Fra2 followed by stimulation 
with exogenous TGF-β1 (10ng/ml) for 72 hours. Inserts show western blot analysis 
confirming Fra2 knock down and 96 well plate layout of treated cells. B) PC3 cells 
exposed to siRNA specific for Fra2 followed by stimulation with exogenous TGF-β1 
(10ng/ml) for 72 hours. Inserts show western blot analysis confirming Fra2 knock down 
and 96 well plate layout of treated cells. Different letters designate statistically significant 





Figure 17: PC3 cells were transiently transfected to silence FosB, cFos, Fra1, and Fra2, 
morphology images were obtained using Ziess microscope at X10 magnification. 
 
TGF-β1 Effect on AP-1 dimerization 
In an attempt to determine which JUN protein could function as FosB dimer 
partner responsible for its effects on in cell migration; PC3 prostate cancer cells were 
seeded at a density of 3 million cells per 10 cm dish and stimulated with TGF-β1 for 4 
hours, the cells were lysed with cell lysis buffer as described previously and lysates used 
to perform a co-immunoprecipitation assay to determine if FosB dimerization with JUN 
proteins was regulated by the presence of TGF-β1. Our data showed that FosB 
dimerization with JunD is minimal and not influenced by TGF-β1 (Figure 18).  The effect 
of TGF-β1 on FosB: JunB dimerization is currently being investigated. The most 
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interesting finding is that TGF-β1 reduced FosB: cJun dimerization (Figure 18). This led 
to an interest in determining whether cJun has a role in prostate cancer cell migration. 
 
Figure 18: PC3 cells were stimulated with TGF-β1 followed by co-immunoprecipitation 
assay to determine the effect of TGF-β1 stimulation on FosB dimerization with JUN 
proteins. 
 
The Role of cJun Protein in Prostate Cancer Cell Migration 
 Our data showed that FosB is essential for basal, TGF-β1-and EGF-induced cell 
migration to occur. Previous studies have shown that FOS proteins must function as 
dimers more specifically heterodimers and that dimerization is a prerequisite for nuclear 
translocation and thus activation of AP-1 dimer complex 71. This finding as well as our 
data indicating that TGF-β1 stimulation decreases cJun: FosB dimerization led to a new 
found interest in the role of cJun in FosB effects, specifically in TGF-β1 signaling and 
prostate cancer cell migration. cJun was transiently silenced in PC3 cells using siRNA 
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specific for cJun followed by transwell migration assay. Our data showed that cJun 
knock-down led to significant increase (P<0.05) in basal, TGF-β1-and EGF-induced cell 
migration (Figure 19). Using DU145 prostate cancer cells that were stably transfected in 
our lab to over-express cJun; we determined that over-expression of cJun leads to a 
significant decrease (P<0.05) in basal cell migration (Figure 20). We are currently 
working on transiently over-expressing cJun in PC3 prostate cancer which will be 
followed by cell migration assays, as well knocking down JunB and JunD and 
determining their effects if any on prostate cancer cell migration. 
 
Figure 19: PC3 cells transiently transfected to knock down cJun and stimulated with 10 
ng/ml of TGF-β1 and EGF followed by transwell migration assay, insert showing western 
blot image confirming cJun knock down. Different letters designate statistically 




Figure 20: DU145 cells stably transfected to over express cJun and stimulated with 10 
ng/ml of EGF followed by transwell migration assay. Different letters designate 












In this study, we demonstrate for the first time the role of FOS transcription 
factors in migration and invasion of prostate epithelial cancer cells and the role of cJun in 
prostate cancer cell migration. To determine the role of FOS proteins in prostate cancer 
cell proliferation migration and invasion, we performed two types of experiments: first, 
the effect of TGF-β1 on the Fos family expression levels were determined by western 
blot analysis using different doses and varying times of exposure to TGF-β1; second, 
FOS knock-down was used to determine their roles in TGF-β-regulated prostate cancer 
cell proliferation, migration, and invasion. The key findings in this study are that 1) TGF-
β1 induces and increased expression of FosB in prostate epithelial cancer cells, 2) FosB is 
essential for migration and invasion to occur in prostate cancer cells, and 3) FosB is 
required for TGF-β1-and EGF-induced cell migration and invasion, 4) TGF-β1 induces 
increased protein expression of Fra2 in PC3 cells only, 5) Fra2 is necessary for basal and 
TGF-β1 induced cell proliferation in PC3 cells, 6) TGF-β1 decreases FosB : cJun 




Knockdown increases cell migration.AP-1 family of transcription factors are a part of the 
complex immediate early genomic response of a variety of cells to transmembrane 
signaling agents.217 Additional complexity results from the variety of possible Jun dimers 
and the JUN-FOS heterodimers and from potential dimer formation between JUN or FOS 
and other leucine zipper proteins.217 JUN and FOS proteins share extensive homology 
within the leucine zipper and basic domains. However, despite their homology, these 
proteins display different transcriptional activity.221 The FOS proteins contribute distinct 
functions towards the activity of the AP-1 heterodimers. For example, c-Fos can both 
activate and repress transcription,79 the full-length Fos B is a transcriptional activator241 
and a naturally occurring short form of FosB inhibits AP-1 transactivation.242 The Fos-
related antigens, Fra-1 and Fra-2 lack functional transactivation domains and are poor 
transcriptional activators.242 We believed that an alteration in the composition of AP-1 
either directly or indirectly regulates cell growth and motility, which in turn pushes the 
normal cell into pre-malignant or malignant state. Therefore we analyzed the effect of 
TGF-β1 on Fos mRNA and protein expression in both normal as well as different 
prostate cancer cell lines. The most interesting observation was an immediate increase in 
FosB expression both at the mRNA and the protein levels in prostate cancer cells as well 
as increased Fra2 protein expression in PC3 cells only.  
TGF-β super family signaling is well known as a key regulator of many biological 
processes31, 49, 230, 243 including differential effects on cell proliferation and migration in 
prostate cancer cells.31, 49, 243 These differential effects of TGF-β during different stages of 




intracellular signals that are required to elicit different biological responses to TGF-β.  A 
loss of TGF-β receptors and/or Smad proteins has been shown to result in TGF-β 
resistance in cancer cells.237, 244-245 However, most cancer cells retain classical TGF-β 
signaling components throughout cancer progression but modify or recruit additional 
signaling pathways to exert novel or different biological effects.237 Our data shows that 
TGF-β1 increases FosB expression in prostate cancer cells, which, in turn, mediates its 
effects on migration and invasion but does not play a role in TGF-β1 effects on cell 
proliferation. Thus TGF-β1 induction of FosB may represent a shift in intracellular 
signaling involved in the escape from inhibition of proliferation to the stimulation of 
more migratory and invasive behavior in advanced stages of prostate cancer.246 TGF-β1 
reduces the dimer formation between cJun and FosB; our data demonstrates that the 
presence of cJun contributes to inhibition of cell migration; this information could shed 
light on the dual role of TGF-β1 prostate cancer cell progression, a role that could involve 
the regulation of AP-1 dimer formation as least in the case of cell migration.  
While essential to normal development and homeostasis, the process of cellular 
migration is also a trait essential for metastasis. Enhanced migration is key across the 
metastatic cascade and is involved in the initial scattering of cells and migration from the 
primary tumor.189 Numerous proteins and pathways have been implicated in altering the 
migratory potentials of cancer cells and therefore their aggressive nature.  Given its 
essential role in cancer progression, treatments that inhibit cell migration or such 
proteins/pathways involved in enhancing cellular motility represent an attractive strategy 




activating domain as seen in cFos and FosB, they might exert inhibitory functions on 
tumor growth. Yet recent data point to a positive effect of Fra1, and partly Fra2, on tumor 
progression in many tumor types.191, 214 Our data suggests that Fra2 plays an important role 
in cell proliferation of aggressive prostate cancer cells but does not have the same effect 
on prostate cancer cells in the early stages of development. In contrast to the bulk of data 
on the function of cFos and Fra1, far less is known about the role of FosB and its smaller 
splice variant ΔFosB which is often expressed more strongly than Fra1 in clinical cancer 
tissues.214, 247 Although, the FOS family of proteins has been extensively studied as 
immediate early genes, the role of FosB in cancer cell proliferation and migration and 
invasion has not been previously investigated.246 There are also no studies demonstrating 
the role of cJun in prostate cancer cell migration. Our data shows that transient silencing 
of FosB with or without the presence of TGF-β1 has no effect on prostate cancer cell 
proliferation but significantly reduces cell migration and invasion. Numerous studies 
have demonstrated that TGF-β1 induces the migration and invasion of prostate cancer 
cells; however, we show in this study that TGF-β1 is unable to induce prostate cancer cell 
migration and invasion without FosB. The data also suggests that epidermal growth 
factor (EGF), a potent mitogenic factor that plays an important role in the growth, 
proliferation and differentiation of numerous cell types is unable to induce migration and 
invasion in prostate cancer cells in the absence of FosB; further confirming that FosB 
does indeed have a major role in migration and invasion of prostate cancer cells. Thus the 
differences in migratory and invasive behavior observed in different stages of prostate 




role in the aggressive phenotype observed in prostate cancer, thus inhibition of FosB 
activity may serve as a therapeutic tool in the management of prostate cancer. 
TGF-β1 is known to switch from being a tumor suppressor in early stage prostate 
cancer to becoming a tumor promoter in the later stages of the disease. Our data suggests 
that TGF-β1 is unable to induce and increase in cell proliferation without the presence of 
Fra2 in PC3 cells which is used in this study to represent an advanced stage prostate 
cancer. This further supports the idea of AP-1 proteins playing essential roles in TGF-β1 
induced prostate cancer cell progression. 
Our data also suggests that TGF-β1 is able to reduce dimer formation between 
cJun which we have shown to be necessary for inhibition of prostate cancer cell 
migration and FosB which we also shown to be essential for prostate cancer cell 
migration to occur. This study has further implicated that targeting AP-1 proteins could 








In conclusion, our results obtained using human prostate cancer cell lines suggest 
that the transcription factors FosB, Fra2 and cJun may be important regulators of TGF-β1 
effects on proliferation, migration and invasion in human prostate cancer cells. The 
functions of AP-1 proteins have been known to be modulated in four major ways: 1) 
changes in protein expression, 2) variations in dimer partners, 3) changes in subcellular 
localization and 4) changes in phosphorylation. Our data indicates that TGF-β1 is able to 
regulate AP-1 by varying their expression, subcellular localization and dimerization. This 
was seen as an increase in FosB and Fra2 protein expression, an increase in FosB nuclear 
localization, and a decrease in FosB: cJun dimerization as a result of prostate cancer cell 
stimulation with TGF-β1. Though still elusive, these studies may help to further 
understand TGF-β1 dual role in prostate cancer progression. Further studies are needed to 
decipher the Jun protein partner that is influenced by the presence of TGF-β1 to bind to 
FosB leading eventually to cell migration and invasion. Also, since TGF-β1 does not 
increase cell proliferation in PC3 cells it still remains unclear as to the specific role of 




expression contribute to PC3 cells being insensitive to the growth inhibitory effects of 
TGF-β1.  
Further studies are also needed to completely decipher the role of cJun in 
FosB/TGF-β1 induced cell migration. Further study of the roles of FosB, Fra2 and cJun 
in prostate cancer carcinogenesis, especially in vivo, will be of great importance and will 
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